Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Kenneth Anderson

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Multiple Myeloma

Chemicals & Drugs

Anatomy

Physiology

Living Beings

Mice

Procedures

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Negri Joseph M; McMillin Douglas W; Delmore Jake; Mitsiades Nicholas; Hayden Patrick; Klippel Steffen; Hideshima Teru; Chauhan Dharminder; Munshi Nikhil C; Buser Carolyn A; Pollard John; Richardson Paul G; Anderson Kenneth C; Mitsiades Constantine S
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
Vogl Dan T; Stadtmauer Edward A; Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Facon Thierry; Harousseau Jean-Luc; Boral Anthony; Neuwirth Rachel; Anderson Kenneth C
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Anderson Kenneth C; Alsina Melissa; Bensinger William; Biermann J Sybil; Chanan-Khan Asher; Cohen Adam D; Devine Steven; Djulbegovic Benjamin; Gasparetto Cristina; Huff Carol Ann; Jagasia Madan; Medeiros Bruno C; Meredith Ruby; Raje Noopur; Schriber Jeffrey; Singhal Seema; Somlo George; Stockerl-Goldstein Keith; Tricot Guido; Vose Julie M; Weber Donna; Yahalom Joachim; Yunus Furhan
NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Kenneth Anderson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Negri Joseph M; McMillin Douglas W; Delmore Jake; Mitsiades Nicholas; Hayden Patrick; Klippel Steffen; Hideshima Teru; Chauhan Dharminder; Munshi Nikhil C; Buser Carolyn A; Pollard John; Richardson Paul G; Anderson Kenneth C; Mitsiades Constantine S
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
British journal of haematology 2009;147(5):672-6.
2009: Vogl Dan T; Stadtmauer Edward A; Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Facon Thierry; Harousseau Jean-Luc; Boral Anthony; Neuwirth Rachel; Anderson Kenneth C
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
British journal of haematology 2009;147(4):531-4.
2009: Anderson Kenneth C; Alsina Melissa; Bensinger William; Biermann J Sybil; Chanan-Khan Asher; Cohen Adam D; Devine Steven; Djulbegovic Benjamin; Gasparetto Cristina; Huff Carol Ann; Jagasia Madan; Medeiros Bruno C; Meredith Ruby; Raje Noopur; Schriber Jeffrey; Singhal Seema; Somlo George; Stockerl-Goldstein Keith; Tricot Guido; Vose Julie M; Weber Donna; Yahalom Joachim; Yunus Furhan
NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(9):908-42.
2009: Chauhan Dharminder; Singh Ajita V; Brahmandam Mohan; Carrasco Ruben; Bandi Madhavi; Hideshima Teru; Bianchi Giada; Podar Klaus; Tai Yu-Tzu; Mitsiades Constantine; Raje Noopur; Jaye David L; Kumar Shaji K; Richardson Paul; Munshi Nikhil; Anderson Kenneth C
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
Cancer cell 2009;16(4):309-23.
2009: Ngo Hai T; Azab Abdel Kareem; Farag Mena; Jia Xiaoying; Melhem Molly M; Runnels Judith; Roccaro Aldo M; Azab Feda; Sacco Antonio; Leleu Xavier; Anderson Kenneth C; Ghobrial Irene M
Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):6035-41.
2009: Blotta Simona; Tassone Pierfrancesco; Prabhala Rao H; Tagliaferri Piersandro; Cervi David; Amin Samir; Jakubikova Jana; Tai Yu-Tzu; Podar Klaus; Mitsiades Constantine S; Zullo Alessandro; Franco Brunella; Anderson Kenneth C; Munshi Nikhil C
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.
Blood 2009;114(15):3276-84.
2009: Pozzi Samantha; Vallet Sonia; Mukherjee Siddhartha; Cirstea Diana; Vaghela Nileshwari; Santo Loredana; Rosen Eyal; Ikeda Hiroshi; Okawa Yutaka; Kiziltepe Tanyel; Schoonmaker Jesse; Xie Wanling; Hideshima Teru; Weller Edie; Bouxsein Mary L; Munshi Nikhil C; Anderson Kenneth C; Raje Noopur
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(18):5829-39.
2009: Dutta-Simmons Jui; Zhang Yunyu; Gorgun Gullu; Gatt Moshe; Mani Mala; Hideshima Teru; Takada Kohichi; Carlson Nicole E; Carrasco Daniel E; Tai Yu-Tzu; Raje Noopur; Letai Anthony G; Anderson Kenneth C; Carrasco Daniel R
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.
Blood 2009;114(13):2699-708.
2009: Kumar Shaji; Giralt Sergio; Stadtmauer Edward A; Harousseau Jean L; Palumbo Antonio; Bensinger William; Comenzo Raymond L; Lentzsch Suzanne; Munshi Nikhil; Niesvizky Ruben; San Miguel Jesus; Ludwig Heinz; Bergsagel Leif; Blade Joan; Lonial Sagar; Anderson Kenneth C; Tosi Patrizia; Sonneveld Pieter; Sezer Orhan; Vesole David; Cavo Michele; Einsele Hermann; Richardson Paul G; Durie Brian G M; Rajkumar S Vincent;
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Blood 2009;114(9):1729-35.
2009: McMillin Douglas W; Ooi Melissa; Delmore Jake; Negri Joseph; Hayden Patrick; Mitsiades Nicolas; Jakubikova Jana; Maira Sauveur-Michel; Garcia-Echeverria Carlos; Schlossman Robert; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C; Mitsiades Constantine S
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Cancer research 2009;69(14):5835-42.
2009: Raab Marc S; Podar Klaus; Breitkreutz Iris; Richardson Paul G; Anderson Kenneth C
Multiple myeloma.
Lancet 2009;374(9686):324-39.
2009: Richardson Paul G; Xie Wanling; Mitsiades Constantine; Chanan-Khan Asher A; Lonial Sagar; Hassoun Hani; Avigan David E; Oaklander Anne Louise; Kuter David J; Wen Patrick Y; Kesari Santosh; Briemberg Hannah R; Schlossman Robert L; Munshi Nikhil C; Heffner L Thompson; Doss Deborah; Esseltine Dixie-Lee; Weller Edie; Anderson Kenneth C; Amato Anthony A
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3518-25.
2009: Richardson Paul; Jagannath Sundar; Hussein Mohamad; Berenson James; Singhal Seema; Irwin David; Williams Stephanie F; Bensinger William; Badros Ashraf Z; Vescio Robert; Kenvin Laurie; Yu Zhinuan; Olesnyckyj Marta; Zeldis Jerome; Knight Robert; Anderson Kenneth C
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Blood 2009;114(4):772-8.
2009: Azab Abdel Kareem; Azab Feda; Blotta Simona; Pitsillides Costas M; Thompson Brian; Runnels Judith M; Roccaro Aldo M; Ngo Hai T; Melhem Molly R; Sacco Antonio; Jia Xiaoying; Anderson Kenneth C; Lin Charles P; Rollins Barrett J; Ghobrial Irene M
RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.
Blood 2009;114(3):619-29.
2009: Hideshima Teru; Ikeda Hiroshi; Chauhan Dharminder; Okawa Yutaka; Raje Noopur; Podar Klaus; Mitsiades Constantine; Munshi Nikhil C; Richardson Paul G; Carrasco Ruben D; Anderson Kenneth C
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Blood 2009;114(5):1046-52.
2009: Fulciniti Mariateresa; Tassone Pierfrancesco; Hideshima Teru; Vallet Sonia; Nanjappa Puru; Ettenberg Seth A; Shen Zhenxin; Patel Nipun; Tai Yu-Tzu; Chauhan Dharminder; Mitsiades Constantine; Prabhala Rao; Raje Noopur; Anderson Kenneth C; Stover David R; Munshi Nikhil C
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
Blood 2009;114(2):371-9.
2009: Roccaro Aldo M; Sacco Antonio; Thompson Brian; Leleu Xavier; Azab Abdel Kareem; Azab Feda; Runnels Judith; Jia Xiaoying; Ngo Hai T; Melhem Molly R; Lin Charles P; Ribatti Domenico; Rollins Barrett J; Witzig Thomas E; Anderson Kenneth C; Ghobrial Irene M
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.
Blood 2009;113(26):6669-80.
2009: Laubach Jacob P; Mitsiades Constantine S; Roccaro Aldo M; Ghobrial Irene M; Anderson Kenneth C; Richardson Paul G
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
Leukemia & lymphoma 2009;50(5):694-702.
2009: Hideshima Teru; Chauhan Dharminder; Kiziltepe Tanyel; Ikeda Hiroshi; Okawa Yutaka; Podar Klaus; Raje Noopur; Protopopov Alexei; Munshi Nikhil C; Richardson Paul G; Carrasco Ruben D; Anderson Kenneth C
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.
Blood 2009;113(21):5228-36.
2009: Anderson Kenneth C
Proteasome inhibitors in multiple myeloma.
Seminars in oncology 2009;36(2 Suppl 1):S20-6.
2009: Mitsiades Constantine S; Hideshima Teru; Chauhan Dharminder; McMillin Douglas W; Klippel Steffen; Laubach Jacob P; Munshi Nikhil C; Anderson Kenneth C; Richardson Paul G
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Seminars in hematology 2009;46(2):166-75.
2009: Tai Yu-Tzu; Soydan Ender; Song Weihua; Fulciniti Mariateresa; Kim Kihyun; Hong Fangxin; Li Xian-Feng; Burger Peter; Rumizen Matthew J; Nahar Sabikun; Podar Klaus; Hideshima Teru; Munshi Nikhil C; Tonon Giovanni; Carrasco Ruben D; Afar Daniel E H; Anderson Kenneth C
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Blood 2009;113(18):4309-18.
2009: Azab Abdel Kareem; Runnels Judith M; Pitsillides Costas; Moreau Anne-Sophie; Azab Feda; Leleu Xavier; Jia Xiaoying; Wright Renee; Ospina Beatriz; Carlson Alicia L; Alt Clemens; Burwick Nicholas; Roccaro Aldo M; Ngo Hai T; Farag Mena; Melhem Molly R; Sacco Antonio; Munshi Nikhil C; Hideshima Teru; Rollins Barrett J; Anderson Kenneth C; Kung Andrew L; Lin Charles P; Ghobrial Irene M
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Blood 2009;113(18):4341-51.
2009: Roccaro Aldo M; Sacco Antonio; Chen Changzhong; Runnels Judith; Leleu Xavier; Azab Feda; Azab Abdel Kareem; Jia Xiaoying; Ngo Hai T; Melhem Molly R; Burwick Nicholas; Varticovski Lyuba; Novina Carl D; Rollins Barrett J; Anderson Kenneth C; Ghobrial Irene M
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
Blood 2009;113(18):4391-402.
2009: Podar Klaus; Tai Yu-Tzu; Hideshima Teru; Vallet Sonia; Richardson Paul G; Anderson Kenneth C
Emerging therapies for multiple myeloma.
Expert opinion on emerging drugs 2009;14(1):99-127.
2009: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; Bladé Joan; Boccadoro Mario; Cavenagh Jamie D; Boral Anthony L; Esseltine Dixie-Lee; Wen Patrick Y; Amato Anthony A; Anderson Kenneth C; San Miguel Jesus
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
British journal of haematology 2009;144(6):895-903.
2009: Raab Marc S; Breitkreutz Iris; Tonon Giovanni; Zhang Jing; Hayden Patrick J; Nguyen Thu; Fruehauf Johannes H; Lin Boris K; Chauhan Dharminder; Hideshima Teru; Munshi Nikhil C; Anderson Kenneth C; Podar Klaus
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.
Blood 2009;113(7):1513-21.
2009: Burger Renate; Le Gouill Steven; Tai Yu-Tzu; Shringarpure Reshma; Tassone Pierfrancesco; Neri Paola; Podar Klaus; Catley Laurence; Hideshima Teru; Chauhan Dharminder; Caulder Eian; Neilan Claire L; Vaddi Kris; Li Jun; Gramatzki Martin; Fridman Jordan S; Anderson Kenneth C
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
Molecular cancer therapeutics 2009;8(1):26-35.
2009: Treon Steven P; Soumerai Jacob D; Branagan Andrew R; Hunter Zachary R; Patterson Christopher J; Ioakimidis Leukothea; Chu Luis; Musto Paul; Baron Ari D; Nunnink Johannes C; Kash Joseph J; Terjanian Terenig O; Hyman Paul M; Nawfel Elena L; Sharon David J; Munshi Nikhil C; Anderson Kenneth C
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):355-60.
2009: Okawa Yutaka; Hideshima Teru; Steed Paul; Vallet Sonia; Hall Steven; Huang Ken; Rice John; Barabasz Amy; Foley Brianna; Ikeda Hiroshi; Raje Noopur; Kiziltepe Tanyel; Yasui Hiroshi; Enatsu Sotaro; Anderson Kenneth C
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.
Blood 2009;113(4):846-55.
2008: Nelson Erik A; Walker Sarah R; Kepich Alicia; Gashin Laurie B; Hideshima Teru; Ikeda Hiroshi; Chauhan Dharminder; Anderson Kenneth C; Frank David A
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.
Blood 2008;112(13):5095-102.
2008: Treon Steven P; Soumerai Jacob D; Branagan Andrew R; Hunter Zachary R; Patterson Christopher J; Ioakimidis Leukothea; Briccetti Frederick M; Pasmantier Mark; Zimbler Harvey; Cooper Robert B; Moore Maria; Hill John; Rauch Alan; Garbo Lawrence; Chu Luis; Chua Cynthia; Nantel Stephen H; Lovett David R; Boedeker Hans; Sonneborn Henry; Howard John; Musto Paul; Ciccarelli Bryan T; Hatjiharissi Evdoxia; Anderson Kenneth C
Thalidomide and rituximab in Waldenstrom macroglobulinemia.
Blood 2008;112(12):4452-7.
2008: Lee Stephanie J; Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; San Miguel Jesús-F; Crawford Bruce; Massaro Joseph; Dhawan Ravinder; Gupta Sanjay; Anderson Kenneth C
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
British journal of haematology 2008;143(4):511-9.
2008: Jagannath Sundar; Barlogie Bart; Berenson James R; Siegel David S; Irwin David; Richardson Paul G; Niesvizky Ruben; Alexanian Raymond; Limentani Steven A; Alsina Melissa; Esseltine Dixie-Lee; Anderson Kenneth C
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
British journal of haematology 2008;143(4):537-40.
2008: Reese P P; Feldman H I; McBride M A; Anderson K; Asch D A; Bloom R D
Substantial variation in the acceptance of medically complex live kidney donors across US renal transplant centers.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008;8(10):2062-70.
2008: Lonial Sagar; Richardson Paul G; San Miguel Jesús; Sonneveld Pieter; Schuster Michael W; Bladé Joan; Cavenagh Jamie; Rajkumar S Vincent; Jakubowiak Andrzej J; Esseltine Dixie-Lee; Anderson Kenneth C; Harousseau Jean-Luc
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
British journal of haematology 2008;143(2):222-9.
2008: Roccaro Aldo M; Ghobrial Irene M; Blotta Simona; Treon Steven P; Malagola Michele; Anderson Kenneth C; Richardson Paul G; Russo Domenico
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.
Biologics : targets & therapy 2008;2(3):419-31.
2008: Tai Yu-Tzu; Dillon Myles; Song Weihua; Leiba Merav; Li Xian-Feng; Burger Peter; Lee Alfred I; Podar Klaus; Hideshima Teru; Rice Audie G; van Abbema Anne; Jesaitis Lynne; Caras Ingrid; Law Debbie; Weller Edie; Xie Wanling; Richardson Paul; Munshi Nikhil C; Mathiot Claire; Avet-Loiseau Hervé; Afar Daniel E H; Anderson Kenneth C
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Blood 2008;112(4):1329-37.
2008: Mitsiades Constantine S; Ocio Enrique M; Pandiella Atanasio; Maiso Patricia; Gajate Consuelo; Garayoa Mercedes; Vilanova David; Montero Juan Carlos; Mitsiades Nicholas; McMullan Ciaran J; Munshi Nikhil C; Hideshima Teru; Chauhan Dharminder; Aviles Pablo; Otero Gabriel; Faircloth Glynn; Mateos M Victoria; Richardson Paul G; Mollinedo Faustino; San-Miguel Jesus F; Anderson Kenneth C
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Cancer research 2008;68(13):5216-25.
2008: Richardson Paul G; Mitsiades Constantine; Schlossman Robert; Ghobrial Irene; Hideshima Teru; Munshi Nikhil; Anderson Kenneth C
Bortezomib in the front-line treatment of multiple myeloma.
Expert review of anticancer therapy 2008;8(7):1053-72.
2008: Kawano Takeshi; Ahmad Rehan; Nogi Hiroko; Agata Naoki; Anderson Kenneth; Kufe Donald
MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells.
International journal of oncology 2008;33(1):153-9.
2008: Munshi Nikhil C; Mitsiades Constantine; Richardson Paul G; Anderson Kenneth C
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma.
Nature clinical practice. Oncology 2008;5(7):374-5.
2008: Vallet Sonia; Palumbo Antonio; Raje Noopur; Boccadoro Mario; Anderson Kenneth C
Thalidomide and lenalidomide: Mechanism-based potential drug combinations.
Leukemia & lymphoma 2008;49(7):1238-45.
2008: Shammas M A; Koley H; Bertheau R C; Neri P; Fulciniti M; Tassone P; Blotta S; Protopopov A; Mitsiades C; Batchu R B; Anderson K C; Chin A; Gryaznov S; Munshi N C
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(7):1410-8.
2008: San-Miguel Jesús; Harousseau Jean-Luc; Joshua Douglas; Anderson Kenneth C
Individualizing treatment of patients with myeloma in the era of novel agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2761-6.
2008: Okawa Yutaka; Hideshima Teru; Ikeda Hiroshi; Raje Noopur; Vallet Sonia; Kiziltepe Tanyel; Yasui Hiroshi; Enatsu Sotaro; Pozzi Samantha; Breitkreutz Iris; Cirstea Diana; Santo Loredana; Richardson Paul; Anderson Kenneth C
Fatty acid synthase is a novel therapeutic target in multiple myeloma.
British journal of haematology 2008;141(5):659-71.
2008: Ishitsuka Kenji; Hideshima Teru; Neri Paola; Vallet Sonia; Shiraishi Norihiko; Okawa Yutaka; Shen Zhenxin; Raje Noopur; Kiziltepe Tanyel; Ocio Enrique M; Chauhan Dharminder; Tassone Pierfrancesco; Munshi Nikhil; Campbell Robert M; Dios Alfonso De; Shih Chuan; Starling James J; Tamura Kazuo; Anderson Kenneth C
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
British journal of haematology 2008;141(5):598-606.
2008: Leleu Xavier; Eeckhoute Jérôme; Jia Xiaoying; Roccaro Aldo M; Moreau Anne-Sophie; Farag Mena; Sacco Antonio; Ngo Hai T; Runnels Judith; Melhem Molly R; Burwick Nicolas; Azab Abdelkareem; Azab Feda; Hunter Zachary; Hatjiharissi Evdoxia; Carrasco Daniel R; Treon Steven P; Witzig Thomas E; Hideshima Teru; Brown Myles; Anderson Kenneth C; Ghobrial Irene M
Targeting NF-kappaB in Waldenstrom macroglobulinemia.
Blood 2008;111(10):5068-77.
2008: Roccaro Aldo M; Leleu Xavier; Sacco Antonio; Jia Xiaoying; Melhem Molly; Moreau Anne-Sophie; Ngo Hai T; Runnels Judith; Azab Abdelkareem; Azab Feda; Burwick Nicholas; Farag Mena; Treon Steven P; Palladino Michael A; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C; Ghobrial Irene M
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
Blood 2008;111(9):4752-63.
2008: Raje Noopur; Woo Sook-Bin; Hande Karen; Yap Jeffrey T; Richardson Paul G; Vallet Sonia; Treister Nathaniel; Hideshima Teru; Sheehy Niall; Chhetri Shweta; Connell Brendan; Xie Wanling; Tai Yu-Tzu; Szot-Barnes Agnieszka; Tian Mei; Schlossman Robert L; Weller Edie; Munshi Nikhil C; Van Den Abbeele Annick D; Anderson Kenneth C
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2387-95.
2008: San-Miguel J F; Richardson P G; Sonneveld P; Schuster M W; Irwin D; Stadtmauer E A; Facon T; Harousseau J-L; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh J D; Neuwirth R; Boral A L; Esseltine D-L; Anderson K C
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(4):842-9.
2008: McGlynn Katherine A; Gridley Gloria; Mellemkjaer Lene; Brinton Louise A; Anderson Kenneth C; Caporaso Neil E; Landgren Ola; Olsen Jorgen H
Risks of cancer among a cohort of 23,935 men and women with osteoporosis.
International journal of cancer. Journal international du cancer 2008;122(8):1879-84.
2008: Roccaro Aldo M; Leleu Xavier; Sacco Antonio; Moreau Anne-Sophie; Hatjiharissi Evdoxia; Jia Xiaoying; Xu Lian; Ciccarelli Bryan; Patterson Christopher J; Ngo Hai T; Russo Domenico; Vacca Angelo; Dammacco Franco; Anderson Kenneth C; Ghobrial Irene M; Treon Steven P
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(6):1849-58.
2008: Richardson Paul G; Niesvizky Ruben; Anderson Kenneth C; Bladé Joan
Re: When you look matters: the effect of assessment schedule on progression-free survival.
Journal of the National Cancer Institute 2008;100(5):373.
2008: Richardson Paul; Mitsiades Constantine; Colson Kathleen; Reilly Eileen; McBride Laura; Chiao Judy; Sun Linda; Ricker Justin; Rizvi Syed; Oerth Carol; Atkins Barbara; Fearen Ivy; Anderson Kenneth; Siegel David
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
Leukemia & lymphoma 2008;49(3):502-7.
2008: Hideshima Teru; Raje Noopur; Richardson Paul G; Anderson Kenneth C
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma.
Therapeutics and clinical risk management 2008;4(1):129-36.
2008: Huston Alissa; Leleu Xavier; Jia Xiaoying; Moreau Anne-Sophie; Ngo Hai T; Runnels Judith; Anderson Judy; Alsayed Yazan; Roccaro Aldo; Vallet Sonia; Hatjiharissi Evdoxia; Tai Yu-Tsu; Sportelli Peter; Munshi Nikhil; Richardson Paul; Hideshima Teru; Roodman David G; Anderson Kenneth C; Ghobrial Irene M
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):865-74.
2008: Mukherjee Siddhartha; Raje Noopur; Schoonmaker Jesse A; Liu Julie C; Hideshima Teru; Wein Marc N; Jones Dallas C; Vallet Sonia; Bouxsein Mary L; Pozzi Samantha; Chhetri Shweta; Seo Y David; Aronson Joshua P; Patel Chirayu; Fulciniti Mariateresa; Purton Louise E; Glimcher Laurie H; Lian Jane B; Stein Gary; Anderson Kenneth C; Scadden David T
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
The Journal of clinical investigation 2008;118(2):491-504.
2008: Palumbo A; Rajkumar S V; Dimopoulos M A; Richardson P G; San Miguel J; Barlogie B; Harousseau J; Zonder J A; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan G J; Orlowski R Z; Shimizu K; Anderson K C; Boccadoro M; Durie B G; Sonneveld P; Hussein M A;
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(2):414-23.
2008: Chauhan Dharminder; Singh Ajita; Brahmandam Mohan; Podar Klaus; Hideshima Teru; Richardson Paul; Munshi Nikhil; Palladino Michael A; Anderson Kenneth C
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Blood 2008;111(3):1654-64.
2008: Anderson K C; Kyle R A; Rajkumar S V; Stewart A K; Weber D; Richardson P;
Clinically relevant end points and new drug approvals for myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(2):231-9.
2008: Jinushi Masahisa; Vanneman Matthew; Munshi Nikhil C; Tai Yu-Tzu; Prabhala Rao H; Ritz Jerome; Neuberg Donna; Anderson Kenneth C; Carrasco Daniel Ruben; Dranoff Glenn
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(4):1285-90.
2008: Podar K; Gouill S L; Zhang J; Opferman J T; Zorn E; Tai Y-T; Hideshima T; Amiot M; Chauhan D; Harousseau J-L; Anderson K C
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Oncogene 2008;27(6):721-31.
2008: Chauhan Dharminder; Bianchi Giada; Anderson Kenneth C
Targeting the UPS as therapy in multiple myeloma.
BMC biochemistry 2008;9 Suppl 1():S1.
2008: Chauhan Dharminder; Hideshima Teru; Anderson Kenneth C
Targeting proteasomes as therapy in multiple myeloma.
Advances in experimental medicine and biology 2008;615():251-60.
2007: Mitsiades Constantine S; Hayden Patrick J; Anderson Kenneth C; Richardson Paul G
From the bench to the bedside: emerging new treatments in multiple myeloma.
Best practice & research. Clinical haematology 2007;20(4):797-816.
2007: Podar Klaus; Richardson Paul G; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
The malignant clone and the bone-marrow environment.
Best practice & research. Clinical haematology 2007;20(4):597-612.
2007: Hideshima Teru; Anderson Kenneth C
Preclinical studies of novel targeted therapies.
Hematology/oncology clinics of North America 2007;21(6):1071-91, viii-ix.
2007: Mitsiades Constantine S; Anderson Kenneth C; Carrasco Daniel R
Mouse models of human myeloma.
Hematology/oncology clinics of North America 2007;21(6):1051-69, viii.
2007: Mitsiades Constantine S; McMillin Douglas W; Klippel Steffen; Hideshima Teru; Chauhan Dharminder; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.
Hematology/oncology clinics of North America 2007;21(6):1007-34, vii-viii.
2007: Anderson Kenneth C
Multiple myeloma. Preface.
Hematology/oncology clinics of North America 2007;21(6):xiii-xiv.
2007: Sirohi B; Powles R; Harousseau J L; Anderson K C
The evolving background for high-dose treatment for myeloma.
Bone marrow transplantation 2007;40(12):1097-100.
2007: Neri P; Tassone P; Shammas M; Yasui H; Schipani E; Batchu R B; Blotta S; Prabhala R; Catley L; Hamasaki M; Hideshima T; Chauhan D; Jacob G S; Picker D; Venuta S; Anderson K C; Munshi N C
Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(12):2519-26.
2007: Raab M S; Breitkreutz I; Anderson K C
Targeted treatments to improve stem cell outcome: old and new drugs.
Bone marrow transplantation 2007;40(12):1129-37.
2007: Leleu Xavier; Jia Xiaoying; Runnels Judith; Ngo Hai T; Moreau Anne-Sophie; Farag Mena; Spencer Joel A; Pitsillides Costas M; Hatjiharissi Evdoxia; Roccaro Aldo; O'Sullivan Garrett; McMillin Douglas W; Moreno Daisy; Kiziltepe Tanyel; Carrasco Ruben; Treon Steven P; Hideshima Teru; Anderson Kenneth C; Lin Charles P; Ghobrial Irene M
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
Blood 2007;110(13):4417-26.
2007: Hayden Patrick J; Mitsiades Constantine S; Anderson Kenneth C; Richardson Paul G
Novel therapies in myeloma.
Current opinion in hematology 2007;14(6):609-15.
2007: Vallet Sonia; Raje Noopur; Ishitsuka Kenji; Hideshima Teru; Podar Klaus; Chhetri Shweta; Pozzi Samantha; Breitkreutz Iris; Kiziltepe Tanyel; Yasui Hiroshi; Ocio Enrique M; Shiraishi Norihiko; Jin Janice; Okawa Yutaka; Ikeda Hiroshi; Mukherjee Siddhartha; Vaghela Nileshwari; Cirstea Diana; Ladetto Marco; Boccadoro Mario; Anderson Kenneth C
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
Blood 2007;110(10):3744-52.
2007: Richardson Paul G; Sonneveld Pieter; Schuster Michael; Irwin David; Stadtmauer Edward; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; Miguel Jesus San; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Alsina Melissa; Rajkumar S Vincent; Lacy Martha; Jakubowiak Andrzej; Dalton William; Boral Anthony; Esseltine Dixie-Lee; Schenkein David; Anderson Kenneth C
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Blood 2007;110(10):3557-60.
2007: Stewart A K; Chang H; Trudel S; Anderson K C; Richardson P; Alsina M; Reece D; Young S; Sable-Hunt A; Li Z; Keats J; Van Wier S; Ahmann G; Price-Troska T; Giusti K; Bergsagel P L; Chesi M; Fonseca R
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(11):2358-9.
2007: Rajkumar S Vincent; Richardson Paul G; Lacy Martha Q; Dispenzieri Angela; Greipp Philip R; Witzig Thomas E; Schlossman Robert; Sidor Carolyn F; Anderson Kenneth C; Gertz Morie A
Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(20):6162-7.
2007: Podar Klaus; Raab Marc S; Chauhan Dharminder; Anderson Kenneth C
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.
Expert opinion on investigational drugs 2007;16(10):1693-707.
2007: Neri Paola; Kumar Shaji; Fulciniti Maria Teresa; Vallet Sonia; Chhetri Shweta; Mukherjee Sidhartha; Tai Yutzu; Chauhan Dharminder; Tassone Pierfrancesco; Venuta Salvatore; Munshi Nikhil C; Hideshima Teru; Anderson Kenneth C; Raje Noopur
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5903-9.
2007: Breitkreutz Iris; Raab Marc S; Vallet Sonia; Hideshima Teru; Raje Noopur; Chauhan Dharminder; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
British journal of haematology 2007;139(1):55-63.
2007: Hatjiharissi Evdoxia; Xu Lian; Santos Daniel Ditzel; Hunter Zachary R; Ciccarelli Bryan T; Verselis Sigitas; Modica Michael; Cao Yang; Manning Robert J; Leleu Xavier; Dimmock Elizabeth A; Kortsaris Alexandros; Mitsiades Constantine; Anderson Kenneth C; Fox Edward A; Treon Steven P
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
Blood 2007;110(7):2561-4.
2007: Ditzel Santos Daniel; Ho Allen W; Tournilhac Olivier; Hatjiharissi Evdoxia; Leleu Xavier; Xu Lian; Tassone Pierfrancesco; Neri Paola; Hunter Zachary R; Chemaly Mariana A Z; Branagan Andrew R; Manning Robert J; Patterson Christopher J; Moreau Anne Sophie; Ciccarelli Bryan; Adamia Sophia; Kriangkum Jitra; Kutok Jeffery L; Tai Yu-Tzu; Zhang Jiangwen; Pilarski Linda M; Anderson Kenneth C; Munshi Nikhil; Treon Steven P
Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.
Experimental hematology 2007;35(9):1366-75.
2007: Hideshima Teru; Catley Laurence; Raje Noopur; Chauhan Dharminder; Podar Klaus; Mitsiades Constantine; Tai Yu-Tzu; Vallet Sonia; Kiziltepe Tanyel; Ocio Enrique; Ikeda Hiroshi; Okawa Yutaka; Hideshima Hiromasa; Munshi Nikhil C; Yasui Hiroshi; Richardson Paul G; Anderson Kenneth C
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
British journal of haematology 2007;138(6):783-91.
2007: Tai Yu-Tzu; Fulciniti Mariateresa; Hideshima Teru; Song Weihua; Leiba Merav; Li Xian-Feng; Rumizen Matthew; Burger Peter; Morrison Aileen; Podar Klaus; Chauhan Dharminder; Tassone Pierfrancesco; Richardson Paul; Munshi Nikhil C; Ghobrial Irene M; Anderson Kenneth C
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Blood 2007;110(5):1656-63.
2007: Hideshima Teru; Mitsiades Constantine; Tonon Giovanni; Richardson Paul G; Anderson Kenneth C
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Nature reviews. Cancer 2007;7(8):585-98.
2007: Birmann Brenda M; Giovannucci Edward; Rosner Bernard; Anderson Kenneth C; Colditz Graham A
Body mass index, physical activity, and risk of multiple myeloma.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(7):1474-8.
2007: Younes Hashem; Leleu Xavier; Hatjiharissi Evdoxia; Moreau Anne-Sophie; Hideshima Teru; Richardson Paul; Anderson Kenneth C; Ghobrial Irene M
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(13):3771-5.
2007: Anderson Kenneth C
Introducing the clinical connection.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(13):3761.
2007: Anderson Kenneth C; Hannah Alison L; Pazdur Richard; Farrell Ann T
A strategic framework for novel drug development in multiple myeloma.
British journal of haematology 2007;138(2):153-9.
2007: Catley Laurence; Hideshima Teru; Chauhan Dharminder; Neri Paola; Tassone Pierfrancesco; Bronson Roderick; Song Weihua; Tai Yu-Tzu; Munshi Nikhil C; Anderson Kenneth C
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model.
Experimental hematology 2007;35(7):1038-46.
2007: Mitsiades Constantine S; Mitsiades Nicholas S; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
Journal of cellular biochemistry 2007;101(4):950-68.
2007: Munshi Nikhil C; Mitsiades Constantine S; Richardson Paul G; Anderson Kenneth C
Does maintenance therapy with thalidomide benefit patients with multiple myeloma?
Nature clinical practice. Oncology 2007;4(7):394-5.
2007: Kiziltepe Tanyel; Hideshima Teru; Ishitsuka Kenji; Ocio Enrique M; Raje Noopur; Catley Laurence; Li Chun-Qi; Trudel Laura J; Yasui Hiroshi; Vallet Sonia; Kutok Jeffery L; Chauhan Dharminder; Mitsiades Constantine S; Saavedra Joseph E; Wogan Gerald N; Keefer Larry K; Shami Paul J; Anderson Kenneth C
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.
Blood 2007;110(2):709-18.
2007: Ghobrial Joanne; Ghobrial Irene M; Mitsiades Constantine; Leleu Xavier; Hatjiharissi Evdoxia; Moreau Anne-Sophie; Roccaro Aldo; Schlossman Robert; Hideshima Teru; Anderson Kenneth C; Richardson Paul
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Oncology (Williston Park, N.Y.) 2007;21(7):785-92; discussion 798-800.
2007: Richardson Paul G; Mitsiades Constantine; Schlossman Robert; Munshi Nikhil; Anderson Kenneth
New drugs for myeloma.
The oncologist 2007;12(6):664-89.
2007: Kiziltepe Tanyel; Hideshima Teru; Catley Laurence; Raje Noopur; Yasui Hiroshi; Shiraishi Norihiko; Okawa Yutaka; Ikeda Hiroshi; Vallet Sonia; Pozzi Samantha; Ishitsuka Kenji; Ocio Enrique M; Chauhan Dharminder; Anderson Kenneth C
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.
Molecular cancer therapeutics 2007;6(6):1718-27.
2007: Bae Jooeun; Mitsiades Constantine; Tai Yu-Tzu; Bertheau Robert; Shammas Masood; Batchu Ramesh Babu; Li Cheng; Catley Lawrence; Prabhala Rao; Anderson Kenneth C; Munshi Nikhil C
Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(12):7730-7.
2007: Kyle Robert A; Yee Gary C; Somerfield Mark R; Flynn Patrick J; Halabi Susan; Jagannath Sundar; Orlowski Robert Z; Roodman David G; Twilde Patricia; Anderson Kenneth;
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(17):2464-72.
2007: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; San Miguel Jesús-F; Cavenagh Jamie D; Anderson Kenneth C
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
British journal of haematology 2007;137(5):429-35.
2007: Moreau Anne-Sophie; Jia Xiaoying; Ngo Hai T; Leleu Xavier; O'Sullivan Garrett; Alsayed Yazan; Leontovich Alexey; Podar Klaus; Kutok Jeffrey; Daley John; Lazo-Kallanian Suzan; Hatjiharissi Evdoxia; Raab Marc S; Xu Lian; Treon Steven P; Hideshima Teru; Anderson Kenneth C; Ghobrial Irene M
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Blood 2007;109(11):4964-72.
2007: Sukhdeo Kumar; Mani Mala; Zhang Yunyu; Dutta Jui; Yasui Hiroshi; Rooney Melissa D; Carrasco Daniel E; Zheng Mei; He Haiying; Tai Yu-Tzu; Mitsiades Constantine; Anderson Kenneth C; Carrasco Daniel R
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(18):7516-21.
2007: Hatjiharissi Evdoxia; Ngo Hai; Leontovich Alexey A; Leleu Xavier; Timm Michael; Melhem Mona; George Diane; Lu Ganwei; Ghobrial Joanna; Alsayed Yazan; Zeismer Steven; Cabanela Miguel; Nehme Alex; Jia Xiaoying; Moreau Anne Sophie; Treon Steven P; Fonseca Rafael; Gertz Morie A; Anderson Kenneth C; Witzig Thomas E; Ghobrial Irene M
Proteomic analysis of waldenstrom macroglobulinemia.
Cancer research 2007;67(8):3777-84.
2007: Podar Klaus; Richardson Paul G; Chauhan Dharminder; Anderson Kenneth C
Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Expert review of anticancer therapy 2007;7(4):551-66.
2007: Carrasco Daniel R; Sukhdeo Kumar; Protopopova Marina; Sinha Raktim; Enos Miriam; Carrasco Daniel E; Zheng Mei; Mani Mala; Henderson Joel; Pinkus Geraldine S; Munshi Nikhil; Horner James; Ivanova Elena V; Protopopov Alexei; Anderson Kenneth C; Tonon Giovanni; DePinho Ronald A
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.
Cancer cell 2007;11(4):349-60.
2007: Anderson Kenneth C
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
Experimental hematology 2007;35(4 Suppl 1):155-62.
2007: Mulligan George; Mitsiades Constantine; Bryant Barb; Zhan Fenghuang; Chng Wee J; Roels Steven; Koenig Erik; Fergus Andrew; Huang Yongsheng; Richardson Paul; Trepicchio William L; Broyl Annemiek; Sonneveld Pieter; Shaughnessy John D; Bergsagel P Leif; Schenkein David; Esseltine Dixie-Lee; Boral Anthony; Anderson Kenneth C
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Blood 2007;109(8):3177-88.
2007: Alsayed Yazan; Ngo Hai; Runnels Judith; Leleu Xavier; Singha Ujjal K; Pitsillides Costas M; Spencer Joel A; Kimlinger Teresa; Ghobrial Joanna M; Jia Xiaoying; Lu Ganwei; Timm Michael; Kumar Ashok; Côté Daniel; Veilleux Israel; Hedin Karen E; Roodman G David; Witzig Thomas E; Kung Andrew L; Hideshima Teru; Anderson Kenneth C; Lin Charles P; Ghobrial Irene M
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
Blood 2007;109(7):2708-17.
2007: Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson K C
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Oncogene 2007;26(16):2374-80.
2007: Ghobrial Irene M; Leleu Xavier; Hatjiharissi Evdoxia; Hideshima Teru; Mitsiades Constantine; Schlossman Robert; Anderson Kenneth C; Richardson Paul
Emerging drugs in multiple myeloma.
Expert opinion on emerging drugs 2007;12(1):155-63.
2007: Podar Klaus; Anderson Kenneth C
Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies.
Cell cycle (Georgetown, Tex.) 2007;6(5):538-42.
2007: Thomas Roman K; Baker Alissa C; Debiasi Ralph M; Winckler Wendy; Laframboise Thomas; Lin William M; Wang Meng; Feng Whei; Zander Thomas; MacConaill Laura; Lee Jeffrey C; Nicoletti Rick; Hatton Charlie; Goyette Mary; Girard Luc; Majmudar Kuntal; Ziaugra Liuda; Wong Kwok-Kin; Gabriel Stacey; Beroukhim Rameen; Peyton Michael; Barretina Jordi; Dutt Amit; Emery Caroline; Greulich Heidi; Shah Kinjal; Sasaki Hidefumi; Gazdar Adi; Minna John; Armstrong Scott A; Mellinghoff Ingo K; Hodi F Stephen; Dranoff Glenn; Mischel Paul S; Cloughesy Tim F; Nelson Stan F; Liau Linda M; Mertz Kirsten; Rubin Mark A; Moch Holger; Loda Massimo; Catalona William; Fletcher Jonathan; Signoretti Sabina; Kaye Frederic; Anderson Kenneth C; Demetri George D; Dummer Reinhard; Wagner Stephan; Herlyn Meenhard; Sellers William R; Meyerson Matthew; Garraway Levi A
High-throughput oncogene mutation profiling in human cancer.
Nature genetics 2007;39(3):347-51.
2007: Yasui H; Hideshima T; Ikeda H; Ocio E M; Kiziltepe T; Vallet S; Okawa Y; Neri P; Sukhdeo K; Podar K; Chauhan D; Richardson P G; Raje N; Carrasco D R; Anderson K C
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(3):535-40.
2007: Richardson Paul G; Hideshima Teru; Mitsiades Constantine; Anderson Kenneth C
The emerging role of novel therapies for the treatment of relapsed myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):149-62.
2007: Anderson Kenneth C; Alsina Melissa; Bensinger William; Biermann J Sybil; Chanan-Khan Asher; Comenzo Raymond L; De Castro Carlos M; Djulbegovic Benjamin; Farag Sherif; Huff Carol Ann; Meredith Ruby; Schriber Jeffrey; Shrieve Dennis; Singhal Seema; Smith Mitchell R; Stockerl-Goldstein Keith; Vose Julie M; Weber Donna; Yahalom Joachim; Yunus Furhan;
Multiple myeloma. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):118-47.
2007: Podar Klaus; Raab Marc S; Tonon Giovanni; Sattler Martin; Barilà Daniela; Zhang Jing; Tai Yu-Tzu; Yasui Hiroshi; Raje Noopur; DePinho Ronald A; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
Cancer research 2007;67(4):1680-8.
2007: Koreth John; Cutler Corey S; Djulbegovic Benjamin; Behl Rajesh; Schlossman Robert L; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C; Soiffer Robert J; Alyea Edwin P
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2007;13(2):183-96.
2007: Yasui Hiroshi; Hideshima Teru; Ikeda Hiroshi; Jin Janice; Ocio Enrique M; Kiziltepe Tanyel; Okawa Yutaka; Vallet Sonia; Podar Klaus; Ishitsuka Kenji; Richardson Paul G; Pargellis Chris; Moss Neil; Raje Noopur; Anderson Kenneth C
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
British journal of haematology 2007;136(3):414-23.
2007: Chauhan Dharminder; Neri Paola; Velankar Mugdha; Podar Klaus; Hideshima Teru; Fulciniti Mariateresa; Tassone Pierfrancesco; Raje Noopur; Mitsiades Constantine; Mitsiades Nicholas; Richardson Paul; Zawel Leigh; Tran Mary; Munshi Nikhil; Anderson Kenneth C
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Blood 2007;109(3):1220-7.
2007: Podar Klaus; Raab Marc S; Zhang Jing; McMillin Douglas; Breitkreutz Iris; Tai Yu-Tzu; Lin Boris K; Munshi Nikhil; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).
Blood 2007;109(4):1669-77.
2007: de la Fuente Miguel A; Sasahara Yoji; Calamito Marco; Antón Inés M; Elkhal Abdallah; Gallego Maria D; Suresh Koduru; Siminovitch Katherine; Ochs Hans D; Anderson Kenneth C; Rosen Fred S; Geha Raif S; Ramesh Narayanaswamy
WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP).
Proceedings of the National Academy of Sciences of the United States of America 2007;104(3):926-31.
2007: Jagannath S; Richardson P G; Sonneveld P; Schuster M W; Irwin D; Stadtmauer E A; Facon T; Harousseau J-L; Cowan J M; Anderson K C
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(1):151-7.
2007: Richardson Paul; Mitsiades Constantine; Schlossman Robert; Ghobrial Irene; Hideshima Teru; Chauhan Dharminder; Munshi Nikhil; Anderson Kenneth
The treatment of relapsed and refractory multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2007;():317-23.
2007: Podar Klaus; Raje Noopur; Anderson Kenneth C
Inhibition of the TGF-beta signaling pathway in tumor cells.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2007;172():77-97.
2006: Anderson Kenneth C; Vesole David H
Stem cell transplant for first relapse from the multiple myeloma research foundation.
Oncology (Williston Park, N.Y.) 2006;20(14):1818, 1820-1, 1825-6.
2006: Yasui Hiroshi; Hideshima Teru; Anderson Kenneth C
Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia.
Leukemia & lymphoma 2006;47(12):2445-6.
2006: Roccaro A M; Hideshima T; Richardson P G; Russo D; Ribatti D; Vacca A; Dammacco F; Anderson K C
Bortezomib as an antitumor agent.
Current pharmaceutical biotechnology 2006;7(6):441-8.
2006: Podar Klaus; Tonon Giovanni; Sattler Martin; Tai Yu-Tzu; Legouill Steven; Yasui Hiroshi; Ishitsuka Kenji; Kumar Shaji; Kumar Rakesh; Pandite Lini N; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(51):19478-83.
2006: Francis Lanie K; Alsayed Yazan; Leleu Xavier; Jia Xiaoying; Singha Ujjal K; Anderson Judith; Timm Michael; Ngo Hai; Lu Ganwei; Huston Alissa; Ehrlich Lori A; Dimmock Elizabeth; Lentzsch Suzanne; Hideshima Teru; Roodman G David; Anderson Kenneth C; Ghobrial Irene M
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(22):6826-35.
2006: Dalton William; Anderson Kenneth C
Synopsis of a roundtable on validating novel therapeutics for multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(22):6603-10.
2006: Richardson Paul G; Mitsiades Constantine S; Munshi Nikhil C; Anderson Kenneth C
Can thalidomide improve outcome in patients with multiple myeloma?
Nature clinical practice. Oncology 2006;3(11):590-1.
2006: Richardson Paul G; Mitsiades Constantine; Ghobrial Irene; Anderson Kenneth
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Current opinion in oncology 2006;18(6):598-608.
2006: Richardson Paul G; Blood Emily; Mitsiades Constantine S; Jagannath Sundar; Zeldenrust Steven R; Alsina Melissa; Schlossman Robert L; Rajkumar S Vincent; Desikan K Raman; Hideshima Teru; Munshi Nikhil C; Kelly-Colson Kathleen; Doss Deborah; McKenney Mary L; Gorelik Svetlana; Warren Diane; Freeman Andrea; Rich Rebecca; Wu Anfang; Olesnyckyj Marta; Wride Kenton; Dalton William S; Zeldis Jerome; Knight Robert; Weller Edie; Anderson Kenneth C
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Blood 2006;108(10):3458-64.
2006: Catley Laurence; Weisberg Ellen; Kiziltepe Tanyel; Tai Yu-Tzu; Hideshima Teru; Neri Paola; Tassone Pierfrancesco; Atadja Peter; Chauhan Dharminder; Munshi Nikhil C; Anderson Kenneth C
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Blood 2006;108(10):3441-9.
2006: Yasui Hiroshi; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Recent advances in the treatment of Multiple Myeloma.
Current pharmaceutical biotechnology 2006;7(5):381-93.
2006: Mitsiades Constantine S; Mitsiades Nicholas; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Current drug targets 2006;7(10):1341-7.
2006: Chauhan D; Hideshima T; Anderson K C
A novel proteasome inhibitor NPI-0052 as an anticancer therapy.
British journal of cancer 2006;95(8):961-5.
2006: Hideshima Teru; Neri Paola; Tassone Pierfranchesco; Yasui Hiroshi; Ishitsuka Kenji; Raje Noopur; Chauhan Dharminder; Podar Klaus; Mitsiades Constantine; Dang Lenny; Munshi Nikhil; Richardson Paul; Schenkein David; Anderson Kenneth C
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5887-94.
2006: Raje N; Kumar S; Hideshima T; Ishitsuka K; Yasui H; Chhetri S; Vallet S; Vonescu E; Shiraishi N; Kiziltepe T; Elford H L; Munshi N C; Anderson K C
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
British journal of haematology 2006;135(1):52-61.
2006: Shammas Masood A; Neri Paola; Koley Hemanta; Batchu Ramesh B; Bertheau Robert C; Munshi Vidit; Prabhala Rao; Fulciniti Mariateresa; Tai Yu Tzu; Treon Steven P; Goyal Raj K; Anderson Kenneth C; Munshi Nikhil C
Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.
Blood 2006;108(8):2804-10.
2006: Raje Noopur; Hideshima Teru; Anderson Kenneth C
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Expert review of anticancer therapy 2006;6(9):1239-47.
2006: Durie B G M; Harousseau J-L; Miguel J S; Bladé J; Barlogie B; Anderson K; Gertz M; Dimopoulos M; Westin J; Sonneveld P; Ludwig H; Gahrton G; Beksac M; Crowley J; Belch A; Boccadaro M; Cavo M; Turesson I; Joshua D; Vesole D; Kyle R; Alexanian R; Tricot G; Attal M; Merlini G; Powles R; Richardson P; Shimizu K; Tosi P; Morgan G; Rajkumar S V;
International uniform response criteria for multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(9):1467-73.
2006: Anderson Kenneth C
New drugs for multiple myeloma.
Clinical advances in hematology & oncology : H&O 2006;4(8):592-4.
2006: Richardson Paul G; Mitsiades Constantine; Hideshima Teru; Anderson Kenneth C
Lenalidomide in multiple myeloma.
Expert review of anticancer therapy 2006;6(8):1165-73.
2006: Joazeiro Claudio A P; Anderson Kenneth C; Hunter Tony
Proteasome inhibitor drugs on the rise.
Cancer research 2006;66(16):7840-2.
2006: Tournilhac O; Santos D D; Xu L; Kutok J; Tai Y-T; Le Gouill S; Catley L; Hunter Z; Branagan A R; Boyce J A; Munshi N; Anderson K C; Treon S P
Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(8):1275-82.
2006: Shringarpure Reshma; Catley Laurence; Bhole Deepak; Burger Renate; Podar Klaus; Tai Yu-Tzu; Kessler Benedikt; Galardy Paul; Ploegh Hidde; Tassone Pierfrancesco; Hideshima Teru; Mitsiades Constantine; Munshi Nikhil C; Chauhan Dharminder; Anderson Kenneth C
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
British journal of haematology 2006;134(2):145-56.
2006: Tai Yu-Tzu; Li Xian-Feng; Breitkreutz Iris; Song Weihua; Neri Paola; Catley Laurence; Podar Klaus; Hideshima Teru; Chauhan Dharminder; Raje Noopur; Schlossman Robert; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Cancer research 2006;66(13):6675-82.
2006: Jagannath Sundar; Richardson Paul G; Barlogie Bart; Berenson James R; Singhal Seema; Irwin David; Srkalovic Gordan; Schenkein David P; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
Haematologica 2006;91(7):929-34.
2006: Neri Paola; Yasui Hiroshi; Hideshima Teru; Tassone Pierfrancesco; Raje Noopur; Catley Laurence P; Ishitsuka Kenji; Blotta Simona; Kiziltepe Tanyel; Ocio Enrique M; Fulciniti Mariateresa; Kanekal Sarath; Elliott Gary T; Munshi Nikhil C; Anderson Kenneth C
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
British journal of haematology 2006;134(1):37-44.
2006: Mitsiades Constantine S; Mitsiades Nicholas S; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.
European journal of cancer (Oxford, England : 1990) 2006;42(11):1564-73.
2006: Richardson Paul G; Briemberg Hannah; Jagannath Sundar; Wen Patrick Y; Barlogie Bart; Berenson James; Singhal Seema; Siegel David S; Irwin David; Schuster Michael; Srkalovic Gordan; Alexanian Raymond; Rajkumar S Vincent; Limentani Steven; Alsina Melissa; Orlowski Robert Z; Najarian Kevin; Esseltine Dixie; Anderson Kenneth C; Amato Anthony A
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3113-20.
2006: Crawford Lisa J A; Walker Brian; Ovaa Huib; Chauhan Dharminder; Anderson Kenneth C; Morris Treen C M; Irvine Alexandra E
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
Cancer research 2006;66(12):6379-86.
2006: Navas T A; Nguyen A N; Hideshima T; Reddy M; Ma J Y; Haghnazari E; Henson M; Stebbins E G; Kerr I; O'Young G; Kapoun A M; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter A A; Schreiner G F; Anderson K C; Higgins L S
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(6):1017-27.
2006: Santos Daniel Ditzel; Hatjiharissi Evdoxia; Tournilhac Olivier; Chemaly Mariana Z A; Leleu Xavier; Xu Lian; Patterson Christopher; Branagan Andrew R; Manning Robert J; Ho Allen W; Hunter Zachary R; Dimmock Elizabeth A; Kutok Jeffery L; Churchill Winthrop H; Castells Mariana C; Tai Yu-Tzu; Anderson Kenneth C; Treon Steven P
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
Clinical lymphoma & myeloma 2006;6(6):478-83.
2006: Hideshima Teru; Catley Laurence; Yasui Hiroshi; Ishitsuka Kenji; Raje Noopur; Mitsiades Constantine; Podar Klaus; Munshi Nikhil C; Chauhan Dharminder; Richardson Paul G; Anderson Kenneth C
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Blood 2006;107(10):4053-62.
2006: Carrasco Daniel R; Tonon Giovanni; Huang Yongsheng; Zhang Yunyu; Sinha Raktim; Feng Bin; Stewart James P; Zhan Fenghuang; Khatry Deepak; Protopopova Marina; Protopopov Alexei; Sukhdeo Kumar; Hanamura Ichiro; Stephens Owen; Barlogie Bart; Anderson Kenneth C; Chin Lynda; Shaughnessy John D; Brennan Cameron; Depinho Ronald A
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
Cancer cell 2006;9(4):313-25.
2006: Kumar Shaji; Raje Noopur; Hideshima Teru; Ishitsuka Kenji; Podar Klaus; Le Gouille Steven; Chauhan Dharminder; Richardson Paul; Munshi Nikhil C; Anderson Kenneth
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma.
British journal of haematology 2006;132(6):698-704.
2006: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David H; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Anderson Kenneth C
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Cancer 2006;106(6):1316-9.
2006: Podar Klaus; Anderson Kenneth C
Caveolin-1 as a potential new therapeutic target in multiple myeloma.
Cancer letters 2006;233(1):10-5.
2006: Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Current therapeutic uses of lenalidomide in multiple myeloma.
Expert opinion on investigational drugs 2006;15(2):171-9.
2006: Barlogie Bart; Kyle Robert A; Anderson Kenneth C; Greipp Philip R; Lazarus Hillard M; Hurd David D; McCoy Jason; Moore Dennis F; Dakhil Shaker R; Lanier Keith S; Chapman Robert A; Cromer Jeana N; Salmon Sydney E; Durie Brian; Crowley John C
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):929-36.
2006: Yasui Hiroshi; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
British journal of haematology 2006;132(4):385-97.
2006: Mitsiades Constantine S; Mitsiades Nicholas S; McMullan Ciaran J; Poulaki Vassiliki; Kung Andrew L; Davies Faith E; Morgan Gareth; Akiyama Masaharu; Shringarpure Reshma; Munshi Nikhil C; Richardson Paul G; Hideshima Teru; Chauhan Dharminder; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Rosen Neal S; Anderson Kenneth C
Antimyeloma activity of heat shock protein-90 inhibition.
Blood 2006;107(3):1092-100.
2006: Roccaro Aldo Maria; Hideshima Teru; Raje Noopur; Kumar Shaji; Ishitsuka Kenji; Yasui Hiroshi; Shiraishi Norihiko; Ribatti Domenico; Nico Beatrice; Vacca Angelo; Dammacco Franco; Richardson Paul Gerard; Anderson Kenneth Carl
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Cancer research 2006;66(1):184-91.
2006: Catley Laurence; Anderson Kenneth C
Velcade and vitamin C: too much of a good thing?
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(1):3-4.
2006: Richardson Paul; Anderson Kenneth
Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):334-6.
2006: Prabhala Rao H; Neri Paola; Bae Jooeun E; Tassone Pierfrancesco; Shammas Masood A; Allam Charles K; Daley John F; Chauhan Dharminder; Blanchard Elizabeth; Thatte Hemant S; Anderson Kenneth C; Munshi Nikhil C
Dysfunctional T regulatory cells in multiple myeloma.
Blood 2006;107(1):301-4.
2006: Hwang Janice Jin; Ghobrial Irene M; Anderson Kenneth C
New frontiers in the treatment of multiple myeloma.
TheScientificWorldJournal 2006;6():1475-503.
2006: Richardson Paul G; Mitsiades Constantine; Hideshima Teru; Anderson Kenneth C
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Annual review of medicine 2006;57():33-47.
2005: Richardson Paul G; Schlossman Robert; Hideshima Teru; Anderson Kenneth C
New treatments for multiple myeloma.
Oncology (Williston Park, N.Y.) 2005;19(14):1781-92; discussion 1792, 1795-7.
2005: Hideshima Teru; Bradner James E; Chauhan Dharminder; Anderson Kenneth C
Intracellular protein degradation and its therapeutic implications.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8530-3.
2005: Tai Yu-Tzu; Li Xian-Feng; Catley Laurence; Coffey Rory; Breitkreutz Iris; Bae Jooeun; Song Weihua; Podar Klaus; Hideshima Teru; Chauhan Dharminder; Schlossman Robert; Richardson Paul; Treon Steven P; Grewal Iqbal S; Munshi Nikhil C; Anderson Kenneth C
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Cancer research 2005;65(24):11712-20.
2005: Lonial Sagar; Waller Edmund K; Richardson Paul G; Jagannath Sundar; Orlowski Robert Z; Giver Cynthia R; Jaye David L; Francis Dixil; Giusti Sara; Torre Claire; Barlogie Bart; Berenson James R; Singhal Seema; Schenkein David P; Esseltine Dixie-Lee W; Anderson Jessica; Xiao Hugh; Heffner Leonard T; Anderson Kenneth C;
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Blood 2005;106(12):3777-84.
2005: Chen Jing; Lee Benjamin H; Williams Ifor R; Kutok Jeffery L; Mitsiades Constantine S; Duclos Nicole; Cohen Sarah; Adelsperger Jennifer; Okabe Rachel; Coburn Allison; Moore Sandra; Huntly Brian J P; Fabbro Doriano; Anderson Kenneth C; Griffin James D; Gilliland Dwight Gary
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Oncogene 2005;24(56):8259-67.
2005: Chauhan Dharminder; Catley Laurence; Li Guilan; Podar Klaus; Hideshima Teru; Velankar Mugdha; Mitsiades Constantine; Mitsiades Nicolas; Yasui Hiroshi; Letai Anthony; Ovaa Huib; Berkers Celia; Nicholson Benjamin; Chao Ta-Hsiang; Neuteboom Saskia T C; Richardson Paul; Palladino Michael A; Anderson Kenneth C
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Cancer cell 2005;8(5):407-19.
2005: Berenson James R; Jagannath Sundar; Barlogie Bart; Siegel David T; Alexanian Raymond; Richardson Paul G; Irwin David; Alsina Melissa; Rajkumar S Vincent; Srkalovic Gordon; Singhal Seema; Limentani Steven; Niesvizky Ruben; Esseltine Dixie L; Trehu Elizabeth; Schenkein David P; Anderson Kenneth
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Cancer 2005;104(10):2141-8.
2005: Richardson Paul Gerard Guy; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Hideshima Teru; Xiao Hugh; Esseltine Dixie; Schenkein David; Anderson Kenneth C;
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Blood 2005;106(9):2977-81.
2005: Anderson Kenneth C
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Seminars in hematology 2005;42(4 Suppl 4):S3-8.
2005: Anderson Kenneth C; Prince H Miles
Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
Seminars in hematology 2005;42(4 Suppl 4):S1-2.
2005: Anderson Kenneth C; Pazdur Richard; Farrell Ann T
Development of effective new treatments for multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7207-11.
2005: Bruno B; Giaccone L; Rotta M; Anderson K; Boccadoro M
Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(10):1729-38.
2005: Richardson Paul G; Schlossman Robert; Mitsiades Constantine; Hideshima Teru; Munshi Nikhil; Anderson Kenneth
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Clinical lymphoma & myeloma 2005;6(2):84-8.
2005: Chauhan Dharminder; Li Guilan; Podar Klaus; Hideshima Teru; Neri Paola; He Deli; Mitsiades Nicholas; Richardson Paul; Chang Yan; Schindler Joanne; Carver Bradley; Anderson Kenneth C
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Cancer research 2005;65(18):8350-8.
2005: Hideshima Teru; Chauhan Dharminder; Richardson Paul; Anderson Kenneth C
Identification and validation of novel therapeutic targets for multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(26):6345-50.
2005: Altun Mikael; Galardy Paul J; Shringarpure Reshma; Hideshima Teru; LeBlanc Richard; Anderson Kenneth C; Ploegh Hidde L; Kessler Benedikt M
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Cancer research 2005;65(17):7896-901.
2005: Maecker B; von Bergwelt-Baildon M S; Anderson K S; Vonderheide R H; Anderson K C; Nadler L M; Schultze J L
Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients.
Clinical and experimental immunology 2005;141(3):558-62.
2005: Ishitsuka Kenji; Hideshima Teru; Hamasaki Makoto; Raje Noopur; Kumar Shaji; Podar Klaus; Le Gouill Steven; Shiraishi Norihiko; Yasui Hiroshi; Roccaro Aldo M; Tai Yu-Zu; Chauhan Dharminder; Fram Robert; Tamura Kazuo; Jain Jugnu; Anderson Kenneth C
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.
Oncogene 2005;24(38):5888-96.
2005: Ishitsuka Kenji; Hideshima Teru; Hamasaki Makoto; Raje Noopur; Kumar Shaji; Hideshima Hiromasa; Shiraishi Norihiko; Yasui Hiroshi; Roccaro Aldo M; Richardson Paul; Podar Klaus; Le Gouill Steven; Chauhan Dharminder; Tamura Kazuo; Arbiser Jack; Anderson Kenneth C
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.
Blood 2005;106(5):1794-800.
2005: Yasui Hiroshi; Hideshima Teru; Raje Noopur; Roccaro Aldo M; Shiraishi Norihiko; Kumar Shaji; Hamasaki Makoto; Ishitsuka Kenji; Tai Yu-Tzu; Podar Klaus; Catley Laurence; Mitsiades Constantine S; Richardson Paul G; Albert Rainer; Brinkmann Volker; Chauhan Dharminder; Anderson Kenneth C
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Cancer research 2005;65(16):7478-84.
2005: Catley Laurence; Tai Yu-Tzu; Chauhan Dharminder; Anderson Kenneth C
Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2005;8(4):205-18.
2005: Tassone Pierfrancesco; Neri Paola; Kutok Jeffery L; Tournilhac Olivier; Santos Daniel Ditzel; Hatjiharissi Evdoxia; Munshi Vidit; Venuta Salvatore; Anderson Kenneth C; Treon Steven P; Munshi Nikhil C
A SCID-hu in vivo model of human Waldenström macroglobulinemia.
Blood 2005;106(4):1341-5.
2005: Raje Noopur; Kumar Shaji; Hideshima Teru; Roccaro Aldo; Ishitsuka Kenji; Yasui Hiroshi; Shiraishi Norihiko; Chauhan Dharminder; Munshi Nikhil C; Green Simon R; Anderson Kenneth C
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Blood 2005;106(3):1042-7.
2005: Tai Yu-Tzu; Li Xianfeng; Tong Xia; Santos Daniel; Otsuki Takemi; Catley Laurence; Tournilhac Olivier; Podar Klaus; Hideshima Teru; Schlossman Robert; Richardson Paul; Munshi Nikhil C; Luqman Mohammad; Anderson Kenneth C
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
Cancer research 2005;65(13):5898-906.
2005: Kumar S; Raje N; Hideshima T; Ishitsuka K; Roccaro A; Shiraishi N; Hamasaki M; Yasui H; Munshi N C; Richardson P; Figg W D; Anderson K C
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(7):1253-61.
2005: Tassone Pierfrancesco; Neri Paola; Carrasco Daniel R; Burger Renate; Goldmacher Victor S; Fram Robert; Munshi Vidit; Shammas Masood A; Catley Laurence; Jacob Gary S; Venuta Salvatore; Anderson Kenneth C; Munshi Nikhil C
A clinically relevant SCID-hu in vivo model of human multiple myeloma.
Blood 2005;106(2):713-6.
2005: Yasui Hiroshi; Hideshima Teru; Hamasaki Makoto; Roccaro Aldo M; Shiraishi Norihiko; Kumar Shaji; Tassone Pierfrancesco; Ishitsuka Kenji; Raje Noopur; Tai Yu-Tzu; Podar Klaus; Chauhan Dharminder; Leoni Lorenzo M; Kanekal Sarath; Elliott Gary; Munshi Nikhil C; Anderson Kenneth C
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
Blood 2005;106(2):706-12.
2005: Mitsiades Constantine S; Mitsiades Nicholas; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Expert review of anticancer therapy 2005;5(3):465-76.
2005: Richardson Paul G; Sonneveld Pieter; Schuster Michael W; Irwin David; Stadtmauer Edward A; Facon Thierry; Harousseau Jean-Luc; Ben-Yehuda Dina; Lonial Sagar; Goldschmidt Hartmut; Reece Donna; San-Miguel Jesus F; Bladé Joan; Boccadoro Mario; Cavenagh Jamie; Dalton William S; Boral Anthony L; Esseltine Dixie L; Porter Jane B; Schenkein David; Anderson Kenneth C;
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
The New England journal of medicine 2005;352(24):2487-98.
2005: Hideshima Teru; Bradner James E; Wong Jason; Chauhan Dharminder; Richardson Paul; Schreiber Stuart L; Anderson Kenneth C
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(24):8567-72.
2005: Tassone Pierfrancesco; Neri Paola; Burger Renate; Savino Rocco; Shammas Masood; Catley Laurence; Podar Klaus; Chauhan Dharminder; Masciari Serena; Gozzini Antonella; Tagliaferri Pierosandro; Venuta Salvatore; Munshi Nikhil C; Anderson Kenneth C
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4251-8.
2005: Vasir Baldev; Borges Virginia; Wu Zekui; Grosman Daren; Rosenblatt Jacalyn; Irie Masaki; Anderson Kenneth; Kufe Donald; Avigan David
Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation.
British journal of haematology 2005;129(5):687-700.
2005: Hamasaki Makoto; Hideshima Teru; Tassone Pierfrancesco; Neri Paola; Ishitsuka Kenji; Yasui Hiroshi; Shiraishi Norihiko; Raje Noopur; Kumar Shaji; Picker Donald H; Jacob Gary S; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Blood 2005;105(11):4470-6.
2005: Kumar Shaji; Anderson Kenneth C
Drug insight: thalidomide as a treatment for multiple myeloma.
Nature clinical practice. Oncology 2005;2(5):262-70.
2005: Berkers Celia R; Verdoes Martijn; Lichtman Eben; Fiebiger Edda; Kessler Benedikt M; Anderson Kenneth C; Ploegh Hidde L; Ovaa Huib; Galardy Paul J
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
Nature methods 2005;2(5):357-62.
2005: Bellucci Roberto; Alyea Edwin P; Chiaretti Sabina; Wu Catherine J; Zorn Emmanuel; Weller Edie; Wu Bingyan; Canning Christine; Schlossman Robert; Munshi Nikhil C; Anderson Kenneth C; Ritz Jerome
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
Blood 2005;105(10):3945-50.
2005: Podar Klaus; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
Targeting signalling pathways for the treatment of multiple myeloma.
Expert opinion on therapeutic targets 2005;9(2):359-81.
2005: Anderson Kenneth C; Palumbo Antonio;
Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation.
Oncology (Williston Park, N.Y.) 2005;19(4):447-50.
2005: Chauhan Dharminder; Hideshima Teru; Mitsiades Constantine; Richardson Paul; Anderson Kenneth C
Proteasome inhibitor therapy in multiple myeloma.
Molecular cancer therapeutics 2005;4(4):686-92.
2005: Hideshima Teru; Chauhan Dharminder; Ishitsuka Kenji; Yasui Hiroshi; Raje Noopur; Kumar Shaji; Podar Klaus; Mitsiades Constantine; Hideshima Hiromasa; Bonham Lynn; Munshi Nikhil C; Richardson Paul G; Singer Jack W; Anderson Kenneth C
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
Oncogene 2005;24(19):3121-9.
2005: Jagannath Sundar; Barlogie Bart; Berenson James R; Singhal Seema; Alexanian Raymond; Srkalovic Gordan; Orlowski Robert Z; Richardson Paul G; Anderson Jessica; Nix Darrell; Esseltine Dixie L; Anderson Kenneth C;
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Cancer 2005;103(6):1195-200.
2005: Craiu Abie; Saito Yoriko; Limon Ana; Eppich Henry M; Olson Douglas P; Rodrigues Neil; Adams Gregor B; Dombkowski David; Richardson Paul; Schlossman Robert; Choi Peter S; Grogins Jonathan; O'Connor Paula G; Cohen Kenneth; Attar Eyal C; Freshman Jay; Rich Rebecca; Mangano Joseph A; Gribben John G; Anderson Kenneth C; Scadden David T
Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function.
Blood 2005;105(5):2235-8.
2005: Richardson Paul G; Mitsiades Constantine; Hideshima Teru; Anderson Kenneth C
Proteasome inhibition in the treatment of cancer.
Cell cycle (Georgetown, Tex.) 2005;4(2):290-6.
2005: Podar Klaus; Anderson Kenneth C
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.
Blood 2005;105(4):1383-95.
2005: Rajkumar S Vincent; Richardson Paul G; Hideshima Teru; Anderson Kenneth C
Proteasome inhibition as a novel therapeutic target in human cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):630-9.
2005: Treon Steven P; Hansen Mark; Branagan Andrew R; Verselis Sigitas; Emmanouilides Christos; Kimby Eva; Frankel Stanley R; Touroutoglou Nikolaos; Turnbull Barry; Anderson Kenneth C; Maloney David G; Fox Edward A
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):474-81.
2005: Hayashi Toshiaki; Hideshima Teru; Akiyama Masaharu; Podar Klaus; Yasui Hiroshi; Raje Noopur; Kumar Shaji; Chauhan Dharminder; Treon Steven P; Richardson Paul; Anderson Kenneth C
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
British journal of haematology 2005;128(2):192-203.
2005: Treon S P; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan A R; Anderson K C; Frankel S R;
Extended rituximab therapy in Waldenström's macroglobulinemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(1):132-8.
2005: Lin Boris; Catley Laurence; LeBlanc Richard; Mitsiades Constantine; Burger Renate; Tai Yu-Tzu; Podar Klaus; Wartmann Markus; Chauhan Dharminder; Griffin James D; Anderson Kenneth C
Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.
Blood 2005;105(1):350-7.
2005: Mitsiades Constantine S; Mitsiades Nicholas; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Proteasome inhibitors as therapeutics.
Essays in biochemistry 2005;41():205-18.
2005: Richardson Paul G; Mitsiades Constantine S; Hideshima Teru; Anderson Kenneth C
Novel biological therapies for the treatment of multiple myeloma.
Best practice & research. Clinical haematology 2005;18(4):619-34.
2005: Hideshima Teru; Podar Klaus; Chauhan Dharminder; Anderson Kenneth C
Cytokines and signal transduction.
Best practice & research. Clinical haematology 2005;18(4):509-24.
2005: Kinose Fumi; Roscilli Giuseppe; Lamartina Stefania; Anderson Kenneth D; Bonelli Fabio; Spence Stanley G; Ciliberto Gennaro; Vogt Thomas F; Holder Daniel J; Toniatti Carlo; Thut Catherine J
Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor.
Molecular vision 2005;11():366-73.
2005: Chauhan Dharminder; Hideshima Teru; Anderson Kenneth C
Proteasome inhibition in multiple myeloma: therapeutic implication.
Annual review of pharmacology and toxicology 2005;45():465-76.
2004: Anderson Kenneth C
Clinical update: novel targets in multiple myeloma.
Seminars in oncology 2004;31(6 Suppl 16):27-32; discussion 33.
2004: Hussein Mohamad A; Anderson Kenneth C
Role of liposomal anthracyclines in the treatment of multiple myeloma.
Seminars in oncology 2004;31(6 Suppl 13):147-60.
2004: Catley Laurence; Tai Yu-Tzu; Shringarpure Reshma; Burger Renate; Son Moni Thi; Podar Klaus; Tassone Pierfrancesco; Chauhan Dharminder; Hideshima Teru; Denis Louis; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Cancer research 2004;64(23):8746-53.
2004: Weisberg E; Catley L; Kujawa J; Atadja P; Remiszewski S; Fuerst P; Cavazza C; Anderson K; Griffin J D
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(12):1951-63.
2004: Raje Noopur; Kumar Shaji; Hideshima Teru; Ishitsuka Kenji; Chauhan Dharminder; Mitsiades Constantine; Podar Klaus; Le Gouill Steven; Richardson Paul; Munshi Nikhil C; Stirling David I; Antin Joseph H; Anderson Kenneth C
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Blood 2004;104(13):4188-93.
2004: Tassone Pierfrancesco; Goldmacher Victor S; Neri Paola; Gozzini Antonella; Shammas Masood A; Whiteman Kathleen R; Hylander-Gans Linda L; Carrasco Daniel R; Hideshima Teru; Shringarpure Reshma; Shi Jialan; Allam Charles K; Wijdenes John; Venuta Salvatore; Munshi Nikhil C; Anderson Kenneth C
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
Blood 2004;104(12):3688-96.
2004: Hayashi Toshiaki; Hideshima Teru; Nguyen Aaron N; Munoz Olivier; Podar Klaus; Hamasaki Makoto; Ishitsuka Kenji; Yasui Hiroshi; Richardson Paul; Chakravarty Sarvajit; Murphy Alison; Chauhan Dharminder; Higgins Linda S; Anderson Kenneth C
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7540-6.
2004: Mitsiades Constantine S; Mitsiades Nicholas; Munshi Nikhil C; Anderson Kenneth C
Focus on multiple myeloma.
Cancer cell 2004;6(5):439-44.
2004: Hideshima Teru; Podar Klaus; Chauhan Dharminder; Ishitsuka Kenji; Mitsiades Constantine; Tai Yu-Tzu; Hamasaki Makoto; Raje Noopur; Hideshima Hiromasa; Schreiner George; Nguyen Aaron N; Navas Tony; Munshi Nikhil C; Richardson Paul G; Higgins Linda S; Anderson Kenneth C
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Oncogene 2004;23(54):8766-76.
2004: Le Gouill Steven; Podar Klaus; Amiot Martine; Hideshima Teru; Chauhan Dharminder; Ishitsuka Kenji; Kumar Shaji; Raje Noopur; Richardson Paul G; Harousseau Jean-Luc; Anderson Kenneth C
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.
Blood 2004;104(9):2886-92.
2004: Podar Klaus; Shringarpure Reshma; Tai Yu-Tzu; Simoncini Melissa; Sattler Martin; Ishitsuka Kenji; Richardson Paul G; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
Cancer research 2004;64(20):7500-6.
2004: Le Gouill Steven; Podar Klaus; Harousseau Jean-Luc; Anderson Kenneth C
Mcl-1 regulation and its role in multiple myeloma.
Cell cycle (Georgetown, Tex.) 2004;3(10):1259-62.
2004: Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson P G; Niesvizky R; Alexanian R; Limentani S A; Alsina M; Adams J; Kauffman M; Esseltine D-L; Schenkein D P; Anderson K C
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
British journal of haematology 2004;127(2):165-72.
2004: Treon S P; Branagan A R; Hunter Z; Santos D; Tournhilac O; Anderson K C
Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(10):1481-3.
2004: Chauhan Dharminder; Li Guilan; Podar Klaus; Hideshima Teru; Mitsiades Constantine; Schlossman Robert; Munshi Nikhil; Richardson Paul; Cotter Finbarr E; Anderson Kenneth C
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Blood 2004;104(8):2458-66.
2004: Dring Ann M; Davies Faith E; Fenton James A L; Roddam Philippa L; Scott Kathryn; Gonzalez David; Rollinson Sara; Rawstron Andrew C; Rees-Unwin Karen S; Li Cheng; Munshi Nikhil C; Anderson Kenneth C; Morgan Gareth J
A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5692-701.
2004: Richardson Paul; Anderson Kenneth
Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(16):3212-4.
2004: Hideshima Teru; Bergsagel P Leif; Kuehl W Michael; Anderson Kenneth C
Advances in biology of multiple myeloma: clinical applications.
Blood 2004;104(3):607-18.
2004: Anderson Kenneth C;
Multiple myeloma clinical practice guidelines in oncoloqy.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2(4):350-69.
2004: Anderson Kenneth C;
Novel immunomodulatory therapies in the treatment of multiple myeloma.
Oncology (Williston Park, N.Y.) 2004;18(8):988-90.
2004: Richardson Paul; Schlossman Robert; Jagannath Sundar; Alsina Melissa; Desikan Raman; Blood Emily; Weller Edie; Mitsiades Constantine; Hideshima Teru; Davies Faith; Doss Deborah; Freeman Andrea; Bosch Joan; Patin John; Knight Robert; Zeldis Jerome; Dalton William; Anderson Kenneth
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Mayo Clinic proceedings. Mayo Clinic 2004;79(7):875-82.
2004: Tassone Pierfrancesco; Gozzini Antonella; Goldmacher Victor; Shammas Masood A; Whiteman Kathleen R; Carrasco Daniel R; Li Cheng; Allam Charles K; Venuta Salvatore; Anderson Kenneth C; Munshi Nikhil C
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Cancer research 2004;64(13):4629-36.
2004: Richardson Paul; Hideshima Teru; Anderson Kenneth C
An update of novel therapeutic approaches for multiple myeloma.
Current treatment options in oncology 2004;5(3):227-38.
2004: Raje Noopur; Hideshima Teru; Davies Faith E; Chauhan Dharminder; Treon Steven P; Young Gloria; Tai Yu-Tzu; Avigan David; Gong Jianlin; Schlossman Robert L; Richardson Paul; Kufe Donald W; Anderson Kenneth C
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
British journal of haematology 2004;125(3):343-52.
2004: Podar Klaus; Mostoslavsky Gustavo; Sattler Martin; Tai Yu-Tzu; Hayashi Toshiaki; Catley Laurence P; Hideshima Teru; Mulligan Richard C; Chauhan Dharminder; Anderson Kenneth C
Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.
The Journal of biological chemistry 2004;279(20):21658-65.
2004: Podar Klaus; Catley Laurence P; Tai Yu-Tzu; Shringarpure Reshma; Carvalho Pedro; Hayashi Toshiaki; Burger Renate; Schlossman Robert L; Richardson Paul G; Pandite Lini N; Kumar Rakesh; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Blood 2004;103(9):3474-9.
2004: Chauhan Dharminder; Li Guilan; Hideshima Teru; Podar Klaus; Shringarpure Reshma; Mitsiades Constantine; Munshi Nikhil; Yew P Renee; Anderson Kenneth C
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
Oncogene 2004;23(20):3597-602.
2004: Tai Yu-Tzu; Catley Laurence P; Mitsiades Constantine S; Burger Renate; Podar Klaus; Shringpaure Reshma; Hideshima Teru; Chauhan Dharminder; Hamasaki Makoto; Ishitsuka Kenji; Richardson Paul; Treon Steven P; Munshi Nikhil C; Anderson Kenneth C
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
Cancer research 2004;64(8):2846-52.
2004: Chauhan Dharminder; Li Guilan; Podar Klaus; Hideshima Teru; Shringarpure Reshma; Catley Laurence; Mitsiades Constantine; Munshi Nikhil; Tai Yu Tzu; Suh Nanjoo; Gribble Gordon W; Honda Tadashi; Schlossman Robert; Richardson Paul; Sporn Michael B; Anderson Kenneth C
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Blood 2004;103(8):3158-66.
2004: Akiyama Masaharu; Yamada Osamu; Hideshima Teru; Yanagisawa Takaaki; Yokoi Kentaro; Fujisawa Kohji; Eto Yoshikatsu; Yamada Hisashi; Anderson Kenneth C
TNFalpha induces rapid activation and nuclear translocation of telomerase in human lymphocytes.
Biochemical and biophysical research communications 2004;316(2):528-32.
2004: Mitsiades Constantine S; Mitsiades Nicholas S; McMullan Ciaran J; Poulaki Vassiliki; Shringarpure Reshma; Akiyama Masaharu; Hideshima Teru; Chauhan Dharminder; Joseph Marie; Libermann Towia A; García-Echeverría Carlos; Pearson Mark A; Hofmann Francesco; Anderson Kenneth C; Kung Andrew L
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Cancer cell 2004;5(3):221-30.
2004: Chauhan D; Li G; Auclair D; Hideshima T; Podar K; Mitsiades N; Mitsiades C; Chen L B; Munshi N; Saxena S; Anderson K C
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
Apoptosis : an international journal on programmed cell death 2004;9(2):149-55.
2004: LeBlanc Richard; Hideshima Teru; Catley Laurence P; Shringarpure Reshma; Burger Renate; Mitsiades Nicholas; Mitsiades Constantine; Cheema Puneet; Chauhan Dharminder; Richardson Paul G; Anderson Kenneth C; Munshi Nikhil C
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
Blood 2004;103(5):1787-90.
2004: Munshi Nikhil C; Hideshima Teru; Carrasco Daniel; Shammas Masood; Auclair Daniel; Davies Faith; Mitsiades Nicholas; Mitsiades Constantine; Kim Ryung Suk; Li Cheng; Rajkumar S Vincent; Fonseca Rafael; Bergsagel Lief; Chauhan Dharminder; Anderson Kenneth C
Identification of genes modulated in multiple myeloma using genetically identical twin samples.
Blood 2004;103(5):1799-806.
2004: Shammas Masood A; Shmookler Reis Robert J; Li Cheng; Koley Hemanta; Hurley Laurence H; Anderson Kenneth C; Munshi Nikhil C
Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(2):770-6.
2004: Ikeda Takashi; Nakata Yukiko; Kimura Fumihiko; Sato Ken; Anderson Kenneth; Motoyoshi Kazuo; Sporn Michael; Kufe Donald
Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid.
Molecular cancer therapeutics 2004;3(1):39-45.
2004: Mitsiades Constantine S; Mitsiades Nicholas S; McMullan Ciaran J; Poulaki Vassiliki; Shringarpure Reshma; Hideshima Teru; Akiyama Masaharu; Chauhan Dharminder; Munshi Nikhil; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Richon Victoria M; Marks Paul A; Anderson Kenneth C
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(2):540-5.
2004: Anderson Kenneth C
Stem cell transplantation for myeloma.
Current hematology reports 2004;3(1):65-6.
2004: Anderson Kenneth C
Bortezomib therapy for myeloma.
Current hematology reports 2004;3(1):65.
2004: Bellucci Roberto; Wu Catherine J; Chiaretti Sabina; Weller Edie; Davies Faith E; Alyea Edwin P; Dranoff Glenn; Anderson Kenneth C; Munshi Nikhil C; Ritz Jerome
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.
Blood 2004;103(2):656-63.
2004: Richardson Paul G; Hideshima Teru; Mitsiades Constantine; Anderson Kenneth
Proteasome inhibition in hematologic malignancies.
Annals of medicine 2004;36(4):304-14.
2004: Catley Laurence; Anderson Kenneth
Strategies to improve the outcome of stem cell transplantation in multiple myeloma.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(1):9-23.
2003: Hideshima Teru; Chauhan Dharminder; Hayashi Toshiaki; Podar Klaus; Akiyama Masaharu; Mitsiades Constantine; MItsiades Nicholas; Gong Baoqing; Bonham Lynn; de Vries Peter; Munshi Nikhil; Richardson Paul G; Singer Jack W; Anderson Kenneth C
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Cancer research 2003;63(23):8428-36.
2003: Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson K C
Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
Bone marrow transplantation 2003;32(12):1145-51.
2003: Anderson Kenneth
Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: implications for universal irradiation of cellular blood components.
Transfusion 2003;43(12):1652-4.
2003: Burger Renate; Bakker Frank; Guenther Andreas; Baum Wolfgang; Schmidt-Arras Dirk; Hideshima Teru; Tai Yu-Tzu; Shringarpure Reshma; Catley Laurence; Senaldi Giorgio; Gramatzki Martin; Anderson Kenneth C
Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival.
British journal of haematology 2003;123(5):869-78.
2003: Davies Faith E; Dring Ann M; Li Cheng; Rawstron Andrew C; Shammas Masood A; O'Connor Sheila M; Fenton James A L; Hideshima Teru; Chauhan Dharminder; Tai Isabella T; Robinson Elizabeth; Auclair Daniel; Rees Karen; Gonzalez David; Ashcroft A John; Dasgupta Ranjit; Mitsiades Constantine; Mitsiades Nicholas; Chen Lan B; Wong Wing H; Munshi Nikhil C; Morgan Gareth J; Anderson Kenneth C
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.
Blood 2003;102(13):4504-11.
2003: Hideshima Teru; Hayashi Toshiaki; Chauhan Dharminder; Akiyama Masaharu; Richardson Paul; Anderson Kenneth
Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines.
Oncogene 2003;22(54):8797-801.
2003: Hideshima Teru; Chauhan Dharminder; Hayashi Toshiaki; Akiyama Masaharu; Mitsiades Nicholas; Mitsiades Constantine; Podar Klaus; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Oncogene 2003;22(52):8386-93.
2003: Choi Yong Sung; Anderson Kenneth; Mufson R Allan
A workshop on the marrow microenvironment and hematological malignancy.
Cancer research 2003;63(21):7539-41.
2003: Chauhan Dharminder; Li Guilan; Hideshima Teru; Podar Klaus; Mitsiades Constantine; Mitsiades Nicholas; Catley Laurence; Tai Yu Tzu; Hayashi Toshiaki; Shringarpure Reshma; Burger Renate; Munshi Nikhil; Ohtake Yasuyuki; Saxena Satya; Anderson Kenneth C
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.
Blood 2003;102(9):3379-86.
2003: Richardson Paul G; Anderson Kenneth C
Bortezomib: a novel therapy approved for multiple myeloma.
Clinical advances in hematology & oncology : H&O 2003;1(10):596-600.
2003: Anderson Kenneth C
The role of immunomodulatory drugs in multiple myeloma.
Seminars in hematology 2003;40(4 Suppl 4):23-32.
2003: Mitsiades Constantine S; Mitsiades Nicholas S; Bronson Ron T; Chauhan Dharminder; Munshi Nikhil; Treon Steven P; Maxwell Christopher A; Pilarski Linda; Hideshima Teru; Hoffman Robert M; Anderson Kenneth C
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
Cancer research 2003;63(20):6689-96.
2003: Akiyama Masaharu; Hideshima Teru; Shammas Masood A; Hayashi Toshiaki; Hamasaki Makoto; Tai Yu-Tzu; Richardson Paul; Gryaznov Sergei; Munshi Nikhil C; Anderson Kenneth C
Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.
Cancer research 2003;63(19):6187-94.
2003: Chauhan Dharminder; Li Guilan; Shringarpure Reshma; Podar Klaus; Ohtake Yasuyuki; Hideshima Teru; Anderson Kenneth C
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
Cancer research 2003;63(19):6174-7.
2003: Catley Laurence; Weisberg Ellen; Tai Yu-Tzu; Atadja Peter; Remiszewski Stacy; Hideshima Teru; Mitsiades Nicholas; Shringarpure Reshma; LeBlanc Richard; Chauhan Dharminder; Munshi Nikhil C; Schlossman Robert; Richardson Paul; Griffin James; Anderson Kenneth C
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Blood 2003;102(7):2615-22.
2003: Richardson Paul G; Hideshima Teru; Anderson Kenneth C
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
Cancer control : journal of the Moffitt Cancer Center 2003;10(5):361-9.
2003: Shammas Masood A; Shmookler Reis Robert J; Akiyama Masaharu; Koley Hemanta; Chauhan Dharminder; Hideshima Teru; Goyal Raj K; Hurley Laurence H; Anderson Kenneth C; Munshi Nikhil C
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
Molecular cancer therapeutics 2003;2(9):825-33.
2003: Tai Yu-Tzu; Podar Klaus; Catley Laurence; Tseng Yu-Hua; Akiyama Masaharu; Shringarpure Reshma; Burger Renate; Hideshima Teru; Chauhan Dharminder; Mitsiades Nicholas; Richardson Paul; Munshi Nikhil C; Kahn C Ronald; Mitsiades Constantine; Anderson Kenneth C
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.
Cancer research 2003;63(18):5850-8.
2003: Chauhan Dharminder; Li Guilan; Sattler Martin; Podar Klaus; Mitsiades Constantine; Mitsiades Nicholas; Munshi Nikhil; Hideshima Teru; Anderson Kenneth C
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.
Oncogene 2003;22(40):6296-300.
2003: Chauhan Dharminder; Hideshima Teru; Anderson Kenneth C
Apoptotic signaling in multiple myeloma: therapeutic implications.
International journal of hematology 2003;78(2):114-20.
2003: Lee Ann-Hwee; Iwakoshi Neal N; Anderson Kenneth C; Glimcher Laurie H
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(17):9946-51.
2003: Hideshima Teru; Richardson Paul; Anderson Kenneth C
Novel therapeutic approaches for multiple myeloma.
Immunological reviews 2003;194():164-76.
2003: Chauhan D; Anderson K C
Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications.
Apoptosis : an international journal on programmed cell death 2003;8(4):337-43.
2003: Hayashi Toshiaki; Hideshima Teru; Akiyama Masaharu; Raje Noopur; Richardson Paul; Chauhan Dharminder; Anderson Kenneth C
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.
Blood 2003;102(4):1435-42.
2003: Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Targeting proteasome inhibition in hematologic malignancies.
Reviews in clinical and experimental hematology 2003;7(2):191-204.
2003: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Alexanian Raymond; Siegel David; Orlowski Robert Z; Kuter David; Limentani Steven A; Lee Stephanie; Hideshima Teru; Esseltine Dixie-Lee; Kauffman Michael; Adams Julian; Schenkein David P; Anderson Kenneth C
A phase 2 study of bortezomib in relapsed, refractory myeloma.
The New England journal of medicine 2003;348(26):2609-17.
2003: Maecker Britta; Anderson Karen S; von Bergwelt-Baildon Michael S; Weller Edie; Vonderheide Robert H; Richardson Paul G; Schlossman Robert L; Menezes Isaura A; Xia Zhinan; Munshi Nikhil C; Anderson Kenneth C; Nadler Lee M; Schultze Joachim L
Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.
British journal of haematology 2003;121(6):842-8.
2003: Hayashi Toshiaki; Treon Steven P; Hideshima Teru; Tai Yu-Tzu; Akiyama Masaharu; Richardson Paul; Chauhan Dharminder; Grewal Iqbal S; Anderson Kenneth C
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.
British journal of haematology 2003;121(4):592-6.
2003: Orsini Enrica; Bellucci Roberto; Alyea Edwin P; Schlossman Robert; Canning Christine; McLaughlin Stephen; Ghia Paolo; Anderson Kenneth C; Ritz Jerome
Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
Cancer research 2003;63(10):2561-8.
2003: Chauhan Dharminder; Li Guilan; Hideshima Teru; Podar Klaus; Mitsiades Constantine; Mitsiades Nicholas; Munshi Nikhil; Kharbanda Surender; Anderson Kenneth C
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells.
The Journal of biological chemistry 2003;278(20):17593-6.
2003: Mitsiades Nicholas; Mitsiades Constantine S; Richardson Paul G; McMullan Ciaran; Poulaki Vassiliki; Fanourakis Galinos; Schlossman Robert; Chauhan Dharminder; Munshi Nikhil C; Hideshima Teru; Richon Victoria M; Marks Paul A; Anderson Kenneth C
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Blood 2003;101(10):4055-62.
2003: Chauhan Dharminder; Li Guilan; Auclair Daniel; Hideshima Teru; Richardson Paul; Podar Klaus; Mitsiades Nicholas; Mitsiades Constantine; Li Cheng; Kim Ryung Suk; Munshi Nikhil; Chen Lan Bo; Wong Wing; Anderson Kenneth C
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
Blood 2003;101(9):3606-14.
2003: Duffell E; Espié E; Nichols T; Adak G K; De Valk H; Anderson K; Stuart J M
Investigation of an outbreak of E. coli O157 infections associated with a trip to France of schoolchildren from Somerset, England.
Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin 2003;8(4):81-6.
2003: Mitsiades Constantine S; Mitsiades Nicholas; Richardson Paul G; Treon Steven P; Anderson Kenneth C
Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Seminars in oncology 2003;30(2):309-12.
2003: Treon Steven P; Kelliher Abigail; Keele Beverly; Frankel Stanley; Emmanouilides Christos; Kimby Eva; Schlossman Robert; Mitsiades Nicholas; Mitsiades Constantine; Preffer Frederic; Anderson Kenneth C
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
Seminars in oncology 2003;30(2):248-52.
2003: Mitsiades Constantine S; Mitsiades Nicholas; Treon Steven P; Anderson Kenneth C
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias.
Seminars in oncology 2003;30(2):156-60.
2003: Gertz Morie A; Anagnostopoulos Athanasios; Anderson Kenneth; Branagan Andrew R; Coleman Morton; Frankel Stanley R; Giralt Sergio; Levine Todd; Munshi Nikhil; Pestronk Alan; Rajkumar Vincent; Treon Steven P
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Seminars in oncology 2003;30(2):121-6.
2003: Greenstein Stephanie; Krett Nancy L; Kurosawa Yoshihiro; Ma Chunguang; Chauhan Dharminder; Hideshima Teru; Anderson Kenneth C; Rosen Steven T
Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.
Experimental hematology 2003;31(4):271-82.
2003: Tai Yu-Tzu; Podar Klaus; Mitsiades Nicholas; Lin Boris; Mitsiades Constantine; Gupta Deepak; Akiyama Masaharu; Catley Laurence; Hideshima Teru; Munshi Nikhil C; Treon Steven P; Anderson Kenneth C
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.
Blood 2003;101(7):2762-9.
2003: Anderson Kenneth C
New agents and approaches in the treatment of multiple myeloma.
Clinical advances in hematology & oncology : H&O 2003;1(3):151-2.
2003: Mitsiades Nicholas; Mitsiades Constantine S; Richardson Paul G; Poulaki Vassiliki; Tai Yu-Tzu; Chauhan Dharminder; Fanourakis Galinos; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Schlossman Robert; Munshi Nikhil C; Hideshima Teru; Anderson Kenneth C
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Blood 2003;101(6):2377-80.
2003: Anderson Kenneth C
Moving disease biology from the lab to the clinic.
Cancer 2003;97(3 Suppl):796-801.
2003: Podar Klaus; Tai Yu-Tzu; Cole Craig E; Hideshima Teru; Sattler Martin; Hamblin Angela; Mitsiades Nicholas; Schlossman Robert L; Davies Faith E; Morgan Gareth J; Munshi Nikhil C; Chauhan Dharminder; Anderson Kenneth C
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.
The Journal of biological chemistry 2003;278(8):5794-801.
2003: Hideshima Teru; Mitsiades Constantine; Akiyama Masaharu; Hayashi Toshiaki; Chauhan Dharminder; Richardson Paul; Schlossman Robert; Podar Klaus; Munshi Nikhil C; Mitsiades Nicholas; Anderson Kenneth C
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
Blood 2003;101(4):1530-4.
2003: Hahn Theresa; Wingard John R; Anderson Kenneth C; Bensinger William I; Berenson James R; Brozeit Greg; Carver Joseph R; Kyle Robert A; McCarthy Philip L
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2003;9(1):4-37.
2003: Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling D I; Anderson K C
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(1):41-4.
2003: Anderson Kenneth C
Multiple myeloma: how far have we come?
Mayo Clinic proceedings. Mayo Clinic 2003;78(1):15-7.
2003: Akiyama Masaharu; Hideshima Teru; Hayashi Toshiaki; Tai Yu-Tzu; Mitsiades Constantine S; Mitsiades Nicholas; Chauhan Dharminder; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.
Cancer research 2003;63(1):18-21.
2003: Hayashi Toshiaki; Hideshima Teru; Anderson Kenneth C
Novel therapies for multiple myeloma.
British journal of haematology 2003;120(1):10-7.
2003: Hideshima Teru; Akiyama Masaharu; Hayashi Toshiaki; Richardson Paul; Schlossman Robert; Chauhan Dharminder; Anderson Kenneth C
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.
Blood 2003;101(2):703-5.
2002: Anderson Kenneth C
Moving disease biology from the laboratory to the clinic.
Seminars in oncology 2002;29(6 Suppl 17):17-20.
2002: Anderson Kenneth C; Dalton William S
Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery.
Molecular cancer therapeutics 2002;1(14):1361-5.
2002: Hideshima Teru; Anderson Kenneth C
Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
Nature reviews. Cancer 2002;2(12):927-37.
2002: Yamaguchi Toru; Yamauchi Mika; Sugimoto Toshitsugu; Chauhan Dharminder; Anderson Kenneth C; Brown Edward M; Chihara Kazuo
The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferation.
Biochemical and biophysical research communications 2002;299(4):532-8.
2002: Raje Noopur; Anderson Kenneth C
Thalidomide and immunomodulatory drugs as cancer therapy.
Current opinion in oncology 2002;14(6):635-40.
2002: Richardson Paul G; Schlossman Robert L; Weller Edie; Hideshima Teru; Mitsiades Constantine; Davies Faith; LeBlanc Richard; Catley Laurence P; Doss Deborah; Kelly Kathleen; McKenney Mary; Mechlowicz Julie; Freeman Andrea; Deocampo Reggie; Rich Rebecca; Ryoo Joan J; Chauhan Dharminder; Balinski Kathe; Zeldis Jerome; Anderson Kenneth C
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Blood 2002;100(9):3063-7.
2002: Ballen Karen K; Hicks Julie; Dharan Bernie; Ambruso Daniel; Anderson Kenneth; Bianco Celso; Bemiller Lynn; Dickey William; Lottenberg Richard; O'Neill Mary; Popovsky Mark; Skerrett Donna; Sniecinski Irena; Wingard John R
Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors.
Transfusion 2002;42(10):1279-84.
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Chauhan Dharminder; Fanourakis Galinos; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Treon Steven P; Munshi Nikhil C; Richardson Paul G; Hideshima Teru; Anderson Kenneth C
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(22):14374-9.
2002: Akiyama Masaharu; Hideshima Teru; Munshi Nikhil C; Anderson Kenneth C
Telomerase inhibitors as anticancer therapy.
Current medicinal chemistry. Anti-cancer agents 2002;2(5):567-75.
2002: Gupta Deepak; Hideshima Teru; Anderson Kenneth C
Novel biologically based therapeutic strategies in myeloma.
Reviews in clinical and experimental hematology 2002;6(3):301-24.
2002: Lin Boris; Podar Klaus; Gupta Deepak; Tai Yu-Tzu; Li Sigui; Weller Edie; Hideshima Teru; Lentzsch Suzanne; Davies Faith; Li Cheng; Weisberg Ellen; Schlossman Robert L; Richardson Paul G; Griffin James D; Wood Jeanette; Munshi Nikhil C; Anderson Kenneth C
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Cancer research 2002;62(17):5019-26.
2002: LeBlanc Richard; Catley Laurence P; Hideshima Teru; Lentzsch Suzanne; Mitsiades Constantine S; Mitsiades Nicholas; Neuberg Donna; Goloubeva Olga; Pien Christine S; Adams Julian; Gupta Deepak; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Cancer research 2002;62(17):4996-5000.
2002: Chauhan Dharminder; Catley Laurence; Hideshima Teru; Li Guilan; Leblanc Richard; Gupta Deepak; Sattler Martin; Richardson Paul; Schlossman Robert L; Podar Klaus; Weller Edie; Munshi Nikhil; Anderson Kenneth C
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.
Blood 2002;100(6):2187-94.
2002: Ryoo Joan J; Cole Craig Emmitt; Anderson Kenneth C
Novel therapies for multiple myeloma.
Blood reviews 2002;16(3):167-74.
2002: Hayashi Toshiaki; Hideshima Teru; Akiyama Masaharu; Richardson Paul; Schlossman Robert L; Chauhan Dharminder; Munshi Nikhil C; Waxman Samuel; Anderson Kenneth C
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.
Molecular cancer therapeutics 2002;1(10):851-60.
2002: Munshi Nikhil C; Hideshima Teru; Chauhan Dharminder; Richardson Paul; Anderson Kenneth C
Novel biologically based therapies for multiple myeloma.
International journal of hematology 2002;76 Suppl 1():340-1.
2002: Mitsiades Constantine S; Mitsiades Nicholas; Poulaki Vassiliki; Schlossman Robert; Akiyama Masaharu; Chauhan Dharminder; Hideshima Teru; Treon Steven P; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Oncogene 2002;21(37):5673-83.
2002: Gupta Deepak; Podar Klaus; Tai Yu Tzu; Lin Boris; Hideshima Teru; Akiyama Masaharu; LeBlanc Richard; Catley Laurence; Mitsiades Nicholas; Mitsiades Constantine; Chauhan Dharminder; Munshi Nikhil C; Anderson Kenneth C
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
Experimental hematology 2002;30(7):711-20.
2002: Akiyama Masaharu; Hideshima Teru; Hayashi Toshiaki; Tai Yu-Tzu; Mitsiades Constantine S; Mitsiades Nicholas; Chauhan Dharminder; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Cytokines modulate telomerase activity in a human multiple myeloma cell line.
Cancer research 2002;62(13):3876-82.
2002: Brander Christian; Raje Noopur; O'Connor Paula G; Davies Faith; Davis Jennifer; Chauhan Darminder; Hideshima Teru; Martin Jeff; Osmond Dennis; Kedes Dean H; Walker Bruce D; Scadden David T; Anderson Kenneth C
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma.
Blood 2002;100(2):698-700.
2002: Bellucci Roberto; Alyea Edwin P; Weller Edie; Chillemi Antoinette; Hochberg Ephraim; Wu Catherine J; Canning Christine; Schlossman Robert; Soiffer Robert J; Anderson Kenneth C; Ritz Jerome
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.
Blood 2002;99(12):4610-7.
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Chauhan Dharminder; Richardson Paul G; Hideshima Teru; Munshi Nikhil C; Treon Steven P; Anderson Kenneth C
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Blood 2002;99(12):4525-30.
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Chauhan Dharminder; Richardson Paul G; Hideshima Teru; Munshi Nikhil; Treon Steven P; Anderson Kenneth C
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
Blood 2002;99(11):4079-86.
2002: Hideshima Teru; Chauhan Dharminder; Hayashi Toshiaki; Podar Klaus; Akiyama Masaharu; Gupta Deepak; Richardson Paul; Munshi Nikhil; Anderson Kenneth C
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.
Molecular cancer therapeutics 2002;1(7):539-44.
2002: Richardson P; Hideshima T; Anderson K
Thalidomide in multiple myeloma.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2002;56(3):115-28.
2002: Benjamin Richard J; Anderson Kenneth C
What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?
Critical reviews in oncology/hematology 2002;42(2):163-71.
2002: Hideshima Teru; Chauhan Dharminder; Richardson Paul; Mitsiades Constantine; Mitsiades Nicholas; Hayashi Toshiaki; Munshi Nikhil; Dang Lenny; Castro Alfredo; Palombella Vito; Adams Julian; Anderson Kenneth C
NF-kappa B as a therapeutic target in multiple myeloma.
The Journal of biological chemistry 2002;277(19):16639-47.
2002: Lentzsch Suzanne; Rogers Michael S; LeBlanc Richard; Birsner Amy E; Shah Jamshed H; Treston Anthony M; Anderson Kenneth C; D'Amato Robert J
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
Cancer research 2002;62(8):2300-5.
2002: Gong Jianlin; Koido Shigeo; Chen Dongshu; Tanaka Yasuhiro; Huang Lei; Avigan David; Anderson Kenneth; Ohno Tsuneya; Kufe Donald
Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.
Blood 2002;99(7):2512-7.
2002: Akiyama Masaharu; Yamada Osamu; Kanda Naotoshi; Akita Shinobu; Kawano Takeshi; Ohno Tsuneya; Mizoguchi Hideaki; Eto Yoshikatsu; Anderson Kenneth C; Yamada Hisashi
Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors.
Cancer letters 2002;178(2):187-97.
2002: Stevenson F K; Anderson K C
Immunotherapy for multiple myeloma: insights from other models.
Leukemia research 2002;26(4):403-5.
2002: Tai Yu-Tzu; Podar Klaus; Kraeft Stine-Kathrein; Wang Fengfei; Young Gloria; Lin Boris; Gupta Deepak; Chen Lan Bo; Anderson Kenneth C
Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications.
Experimental hematology 2002;30(3):212-20.
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Anderson Kenneth C; Treon Steven P
Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.
Blood 2002;99(6):2162-71.
2002: Podar Klaus; Tai Yu-Tzu; Lin Boris K; Narsimhan Radha P; Sattler Martin; Kijima Takashi; Salgia Ravi; Gupta Deepak; Chauhan Dharminder; Anderson Kenneth C
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
The Journal of biological chemistry 2002;277(10):7875-81.
2002: Chauhan Dharminder; Auclair Daniel; Robinson Elisabeth K; Hideshima Teru; Li Guilan; Podar Klaus; Gupta Deepak; Richardson Paul; Schlossman Robert L; Krett Nancy; Chen Lan Bo; Munshi Nikhil C; Anderson Kenneth C
Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.
Oncogene 2002;21(9):1346-58.
2002: Tai Yu-Tzu; Podar Klaus; Gupta Deepak; Lin Boris; Young Gloria; Akiyama Masaharu; Anderson Kenneth C
CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells.
Blood 2002;99(4):1419-27.
2002: Treon Steven P; Pilarski Linda M; Belch Andrew R; Kelliher Abigail; Preffer Frederic I; Shima Yoshihito; Mitsiades Constantine S; Mitsiades Nicholas S; Szczepek Agnieszka J; Ellman Leonard; Harmon David; Grossbard Michael L; Anderson Kenneth C
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(1):72-81.
2002: Anderson Kenneth C; Boise Lawrence H; Louie Robert; Waxman Samuel
Arsenic trioxide in multiple myeloma: rationale and future directions.
Cancer journal (Sudbury, Mass.) 2002;8(1):12-25.
2002: Anderson Kenneth C; Shaughnessy John D; Barlogie Bart; Harousseau Jean-Luc; Roodman G David
Multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():214-40.
2002: Alyea E; Neuberg D; Mauch P; Marcus K; Freedman A; Webb I; Anderson K; Schlossman R; Fisher D; Gribben J; Ritz J; Soiffer R
Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2002;8(3):139-44.
2002: Richardson Paul; Hideshima Teru; Anderson Kenneth
Thalidomide: emerging role in cancer medicine.
Annual review of medicine 2002;53():629-57.
2001: Gupta D; Treon S P; Shima Y; Hideshima T; Podar K; Tai Y T; Lin B; Lentzsch S; Davies F E; Chauhan D; Schlossman R L; Richardson P; Ralph P; Wu L; Payvandi F; Muller G; Stirling D I; Anderson K C
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(12):1950-61.
2001: Hideshima T; Chauhan D; Podar K; Schlossman R L; Richardson P; Anderson K C
Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Seminars in oncology 2001;28(6):607-12.
2001: D'Amato R J; Lentzsch S; Anderson K C; Rogers M S
Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.
Seminars in oncology 2001;28(6):597-601.
2001: Hideshima T; Nakamura N; Chauhan D; Anderson K C
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.
Oncogene 2001;20(42):5991-6000.
2001: Stewart A K; Vescio R; Schiller G; Ballester O; Noga S; Rugo H; Freytes C; Stadtmauer E; Tarantolo S; Sahebi F; Stiff P; Meharchard J; Schlossman R; Brown R; Tully H; Benyunes M; Jacobs C; Berenson R; White M; DiPersio J; Anderson K C; Berenson J
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(17):3771-9.
2001: Mitsiades N; Mitsiades C S; Poulaki V; Anderson K C; Treon S P
Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
Expert opinion on investigational drugs 2001;10(8):1521-30.
2001: Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
Blood 2001;98(4):934-9.
2001: Mitsiades C S; Treon S P; Mitsiades N; Shima Y; Richardson P; Schlossman R; Hideshima T; Anderson K C
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
Blood 2001;98(3):795-804.
2001: Anderson K C
Novel biologically based therapies for myeloma.
Cancer journal (Sudbury, Mass.) 2001;7 Suppl 1():S19-23.
2001: Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson K C
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
Oncogene 2001;20(33):4519-27.
2001: Anderson K C
Targeted therapy for multiple myeloma.
Seminars in hematology 2001;38(3):286-94.
2001: Podar K; Tai Y T; Davies F E; Lentzsch S; Sattler M; Hideshima T; Lin B K; Gupta D; Shima Y; Chauhan D; Mitsiades C; Raje N; Richardson P; Anderson K C
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Blood 2001;98(2):428-35.
2001: Davies F E; Raje N; Hideshima T; Lentzsch S; Young G; Tai Y T; Lin B; Podar K; Gupta D; Chauhan D; Treon S P; Richardson P G; Schlossman R L; Morgan G J; Muller G W; Stirling D I; Anderson K C
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Blood 2001;98(1):210-6.
2001: Chauhan D; Hideshima T; Rosen S; Reed J C; Kharbanda S; Anderson K C
Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells.
The Journal of biological chemistry 2001;276(27):24453-6.
2001: Mitsiades N; Poulaki V; Mitsiades C S; Anderson K C
Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
Expert opinion on investigational drugs 2001;10(6):1075-84.
2001: Alyea E P; Anderson K C
Allotransplantation for multiple myeloma.
Cancer journal (Sudbury, Mass.) 2001;7(3):166-74.
2001: Treon S P; Agus T B; Link B; Rodrigues G; Molina A; Lacy M Q; Fisher D C; Emmanouilides C; Richards A I; Clark B; Lucas M S; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson K C; Byrd J C
CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(3):272-9.
2001: Treon S P; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson K C
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(3):263-71.
2001: Schultze J L; Anderson K C; Gilleece M H; Gribben J G; Nadler L M
A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2.
British journal of haematology 2001;113(2):455-60.
2001: Anderson K C
Multiple Myeloma. Advances in disease biology: therapeutic implications.
Seminars in hematology 2001;38(2 Suppl 3):6-10.
2001: Hideshima T; Richardson P; Chauhan D; Palombella V J; Elliott P J; Adams J; Anderson K C
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Cancer research 2001;61(7):3071-6.
2001: Schiffer C A; Anderson K C; Bennett C L; Bernstein S; Elting L S; Goldsmith M; Goldstein M; Hume H; McCullough J J; McIntyre R E; Powell B L; Rainey J M; Rowley S D; Rebulla P; Troner M B; Wagnon A H;
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1519-38.
2001: Chauhan D; Anderson K C
Apoptosis in multiple myeloma: therapeutic implications.
Apoptosis : an international journal on programmed cell death 2001;6(1-2):47-55.
2001: Soiffer R J; Weller E; Alyea E P; Mauch P; Webb I L; Fisher D C; Freedman A S; Schlossman R L; Gribben J; Lee S; Anderson K C; Marcus K; Stone R M; Antin J H; Ritz J
CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1152-9.
2001: Dalton W S; Bergsagel P L; Kuehl W M; Anderson K C; Harousseau J L
Multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2001;():157-77.
2001: Waxman S; Anderson K C
History of the development of arsenic derivatives in cancer therapy.
The oncologist 2001;6 Suppl 2():3-10.
2000: Treon S P; Anderson K C
The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.
Seminars in oncology 2000;27(6 Suppl 12):79-85.
2000: Tai Y T; Teoh G; Lin B; Davies F E; Chauhan D; Treon S P; Raje N; Hideshima T; Shima Y; Podar K; Anderson K C
Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(11):6347-55.
2000: Treon S P; Maimonis P; Bua D; Young G; Raje N; Mollick J; Chauhan D; Tai Y T; Hideshima T; Shima Y; Hilgers J; von Mensdorff-Pouilly S; Belch A R; Pilarski L M; Anderson K C
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.
Blood 2000;96(9):3147-53.
2000: Hideshima T; Chauhan D; Shima Y; Raje N; Davies F E; Tai Y T; Treon S P; Lin B; Schlossman R L; Richardson P; Muller G; Stirling D I; Anderson K C
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Blood 2000;96(9):2943-50.
2000: Treon S P; Raje N; Anderson K C
Immunotherapeutic strategies for the treatment of plasma cell malignancies.
Seminars in oncology 2000;27(5):598-613.
2000: Chauhan D; Pandey P; Hideshima T; Treon S; Raje N; Davies F E; Shima Y; Tai Y T; Rosen S; Avraham S; Kharbanda S; Anderson K C
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.
The Journal of biological chemistry 2000;275(36):27845-50.
2000: Crémieux P Y; Barrett B; Anderson K; Slavin M B
Cost of outpatient blood transfusion in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(14):2755-61.
2000: Raje N; Anderson K C
Introduction: the evolving role of bisphosphonate therapy in multiple myeloma.
Blood 2000;96(2):381-3.
2000: Davies F E; Anderson K C
Novel therapeutic targets in multiple myeloma.
European journal of haematology 2000;64(6):359-67.
2000: Raje N; Kica G; Chauhan D; Zhang Y; Teoh G; Treon S P; Hideshima T; Deng J H; Gao S J; Alsina M; Wally J; Davies F E; Tai Y T; Pinkus G S; Pinkus J L; Skinner M; Comenzo R L; Anderson K C
Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2000;7(2):126-32.
2000: Raje N; Anderson K C
Multiple myeloma.
Current treatment options in oncology 2000;1(1):73-82.
2000: Stevenson F K; Anderson K C
Preparing the ground for vaccination against multiple myeloma.
Immunology today 2000;21(4):170-1.
2000: Hideshima T; Chauhan D; Teoh G; Raje N; Treon S P; Tai Y T; Shima Y; Anderson K C
Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):1180-9.
2000: Orsini E; Alyea E P; Schlossman R; Canning C; Soiffer R J; Chillemi A; Neuberg D; Anderson K C; Ritz J
Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
Bone marrow transplantation 2000;25(6):623-32.
2000: Tai Y T; Teoh G; Shima Y; Chauhan D; Treon S P; Raje N; Hideshima T; Davies F E; Anderson K C
Isolation and characterization of human multiple myeloma cell enriched populations.
Journal of immunological methods 2000;235(1-2):11-9.
2000: Teoh G; Tai Y T; Urashima M; Shirahama S; Matsuzaki M; Chauhan D; Treon S P; Raje N; Hideshima T; Shima Y; Anderson K C
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines.
Blood 2000;95(3):1039-46.
2000: Vescio R A; Wu C H; Zheng L; Sheen D; Ma H; Liu J; Stewart A K; Ballester O; Noga S J; Rugo H; Freytes C; Stadtmauer E; Sahebi F; Tarantolo S; Stiff P; Schiller G J; White M; Jacobs C; DiPersio J; Anderson K C; Berenson J R
Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients.
Bone marrow transplantation 2000;25(2):153-60.
2000: Orsini E; Alyea E P; Chillemi A; Schlossman R; McLaughlin S; Canning C; Soiffer R J; Anderson K C; Ritz J
Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2000;6(4):375-86.
2000: Ladetto M; Donovan J W; Harig S; Trojan A; Poor C; Schlossnan R; Anderson K C; Gribben J G
Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2000;6(3):241-53.
2000: Treon S P; Shima Y; Grossbard M L; Preffer F I; Belch A R; Pilarski L M; Anderson K C
Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 1():107-11.
1999: Chauhan D; Hideshima T; Pandey P; Treon S; Teoh G; Raje N; Rosen S; Krett N; Husson H; Avraham S; Kharbanda S; Anderson K C
RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.
Oncogene 1999;18(48):6733-40.
1999: Freedman A S; Neuberg D; Mauch P; Soiffer R J; Anderson K C; Fisher D C; Schlossman R; Alyea E P; Takvorian T; Jallow H; Kuhlman C; Ritz J; Nadler L M; Gribben J G
Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.
Blood 1999;94(10):3325-33.
1999: Treon S P; Shima Y; Preffer F I; Doss D S; Ellman L; Schlossman R L; Grossbard M L; Belch A R; Pilarski L M; Anderson K C
Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Seminars in oncology 1999;26(5 Suppl 14):97-106.
1999: Anderson K
Advances in the biology of multiple myeloma: therapeutic applications.
Seminars in oncology 1999;26(5 Suppl 13):10-22.
1999: Bergsagel D E; Wong O; Bergsagel P L; Alexanian R; Anderson K; Kyle R A; Raabe G K
Benzene and multiple myeloma: appraisal of the scientific evidence.
Blood 1999;94(4):1174-82.
1999: Webb I J; Anderson K C
Risks, costs, and alternatives to platelet transfusions.
Leukemia & lymphoma 1999;34(1-2):71-84.
1999: Gale R P; Park R E; Dubois R W; Anderson K C; Audeh W M; Bergsagel D; Jagannath S; Kyle R A; Oken M M; Perlman M; Rifkin R M; Stone M J; Durie B
Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow autotransplants in newly diagnosed multiple myeloma.
Leukemia & lymphoma 1999;33(5-6):511-9.
1999: Schlossman R L; Anderson K C
Bone marrow transplantation in multiple myeloma.
Current opinion in oncology 1999;11(2):102-8.
1999: Urashima M; Teoh G; Akiyama M; Yuza Y; Anderson K C; Maekawa K
Restoration of p16INK4A protein induces myogenic differentiation in RD rhabdomyosarcoma cells.
British journal of cancer 1999;79(7-8):1032-6.
1999: Chauhan D; Hideshima T; Treon S; Teoh G; Raje N; Yoshihimito S; Tai Y T; Li W; Fan J; DeCaprio J; Anderson K C
Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells.
Cancer research 1999;59(6):1192-5.
1999: Vescio R; Schiller G; Stewart A K; Ballester O; Noga S; Rugo H; Freytes C; Stadtmauer E; Tarantolo S; Sahebi F; Stiff P; Meharchard J; Schlossman R; Brown R; Tully H; Benyunes M; Jacobs C; Berenson R; DiPersio J; Anderson K; Berenson J
Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.
Blood 1999;93(6):1858-68.
1999: Raje N; Gong J; Chauhan D; Teoh G; Avigan D; Wu Z; Chen D; Treon S P; Webb I J; Kufe D W; Anderson K C
Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences.
Blood 1999;93(5):1487-95.
1999: Chauhan D; Bharti A; Raje N; Gustafson E; Pinkus G S; Pinkus J L; Teoh G; Hideshima T; Treon S P; Fingeroth J D; Anderson K C
Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells.
Blood 1999;93(5):1482-6.
1999: Treon S P; Mollick J A; Urashima M; Teoh G; Chauhan D; Ogata A; Raje N; Hilgers J H; Nadler L; Belch A R; Pilarski L M; Anderson K C
Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone.
Blood 1999;93(4):1287-98.
1999: Anderson K C; Lust J A
Role of cytokines in multiple myeloma.
Seminars in hematology 1999;36(1 Suppl 3):14-20.
1999: Anderson K C; Hamblin T J; Traynor A
Management of multiple myeloma today.
Seminars in hematology 1999;36(1 Suppl 3):3-8.
1999: Stevenson F; Anderson K C
Introduction: immunotherapy for multiple myeloma--insights and advances.
Seminars in hematology 1999;36(1 Suppl 3):1-2.
1999: Friedberg J W; Neuberg D; Gribben J G; Mauch P; Anderson K C; Soiffer R J; Takvorian T; Fisher D C; Schlossman R; Jallow H; Kuhlman C; Ritz J; Freedman A S
Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1999;5(4):262-8.
1998: Teoh G; Chen L; Urashima M; Tai Y T; Celi L A; Chen D; Chauhan D; Ogata A; Finberg R W; Webb I J; Kufe D W; Anderson K C
Adenovirus vector-based purging of multiple myeloma cells.
Blood 1998;92(12):4591-601.
1998: Treon S P; Teoh G; Urashima M; Ogata A; Chauhan D; Webb I J; Anderson K C
Anti-estrogens induce apoptosis of multiple myeloma cells.
Blood 1998;92(5):1749-57.
1998: Urashima M; Teoh G; Chauhan D; Ogata A; Shirahama S; Kaihara C; Matsuzaki M; Matsushima H; Akiyama M; Yuza Y; Maekawa K; Anderson K C
MDM2 protein overexpression inhibits apoptosis of TF-1 granulocyte-macrophage colony-stimulating factor-dependent acute myeloblastic leukemia cells.
Blood 1998;92(3):959-67.
1998: Grossbard M L; Fidias P; Kinsella J; O'Toole J; Lambert J M; Blattler W A; Esseltine D; Braman G; Nadler L M; Anderson K C
Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.
British journal of haematology 1998;102(2):509-15.
1998: Soiffer R J; Freedman A S; Neuberg D; Fisher D C; Alyea E P; Gribben J; Schlossman R L; Bartlett-Pandite L; Kuhlman C; Murray C; Freeman A; Mauch P; Anderson K C; Nadler L M; Ritz J
CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
Bone marrow transplantation 1998;21(12):1177-81.
1998: Alyea E P; Soiffer R J; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson K C; Ritz J
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Blood 1998;91(10):3671-80.
1998: Webb I J; Beach M; Daley J F; Schott D M; Anderson K C
Sequential CD34+ and CD4+ cell selection from leukapheresis components.
Journal of hematotherapy 1998;7(2):169-74.
1998: Teoh G; Urashima M; Greenfield E A; Nguyen K A; Lee J F; Chauhan D; Ogata A; Treon S P; Anderson K C
The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells.
The Journal of clinical investigation 1998;101(6):1379-88.
1998: Treon S P; Anderson K C
Interleukin-6 in multiple myeloma and related plasma cell dyscrasias.
Current opinion in hematology 1998;5(1):42-8.
1998: Benson K; Popovsky M A; Hines D; Hume H; Oberman H A; Glassman A B; Pisciotto P T; Thurer R L; Stehling L; Anderson K C
Nationwide survey of home transfusion practices.
Transfusion 1998;38(1):90-6.
1998: Freedman A S; Neuberg D; Gribben J G; Mauch P; Soiffer R J; Fisher D C; Anderson K C; Andersen N; Schlossman R; Kroon M; Ritz J; Aster J; Nadler L M
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):13-8.
1998: Hallek M; Bergsagel P L; Anderson K C
Multiple myeloma: increasing evidence for a multistep transformation process.
Blood 1998;91(1):3-21.
1997: Freedman A; Neuberg D; Mauch P; Gribben J; Soiffer R; Anderson K; Robertson M; Fisher D C; Schlossman R; Kroon M; Rhuda C; Kuhlman C; Ritz J; Nadler L
Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation.
Blood 1997;90(12):4996-5001.
1997: Urashima M; Teoh G; Ogata A; Chauhan D; Treon S P; Sugimoto Y; Kaihara C; Matsuzaki M; Hoshi Y; DeCaprio J A; Anderson K C
Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2173-9.
1997: Webb I J; Soiffer R J; Andersen J W; Cohen C A; Freeman A; Sugrue M; Ritz J; Anderson K C
In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1997;3(5):267-72.
1997: Chauhan D; Pandey P; Ogata A; Teoh G; Krett N; Halgren R; Rosen S; Kufe D; Kharbanda S; Anderson K
Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells.
The Journal of biological chemistry 1997;272(48):29995-7.
1997: Urashima M; Teoh G; Ogata A; Chauhan D; Treon S P; Hoshi Y; DeCaprio J A; Anderson K C
Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(11):1957-63.
1997: Urashima M; DeCaprio J A; Chauhan D; Teoh G; Ogata A; Treon S P; Hoshi Y; Anderson K C
p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells.
Blood 1997;90(10):4106-15.
1997: Teoh G; Urashima M; Ogata A; Chauhan D; DeCaprio J A; Treon S P; Schlossman R L; Anderson K C
MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells.
Blood 1997;90(5):1982-92.
1997: Ogata A; Chauhan D; Teoh G; Treon S P; Urashima M; Schlossman R L; Anderson K C
IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(5):2212-21.
1997: Chauhan D; Pandey P; Ogata A; Teoh G; Treon S; Urashima M; Kharbanda S; Anderson K C
Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism.
Oncogene 1997;15(7):837-43.
1997: Urashima M; Chen B P; Chen S; Pinkus G S; Bronson R T; Dedera D A; Hoshi Y; Teoh G; Ogata A; Treon S P; Chauhan D; Anderson K C
The development of a model for the homing of multiple myeloma cells to human bone marrow.
Blood 1997;90(2):754-65.
1997: Urashima M; Teoh G; Chauhan D; Hoshi Y; Ogata A; Treon S P; Schlossman R L; Anderson K C
Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells.
Blood 1997;90(1):279-89.
1997: Ogata A; Chauhan D; Urashima M; Teoh G; Treon S P; Anderson K C
Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(6):1017-22.
1997: Ohto H; Anderson K C
Are guidelines for use of gamma irradiation for the prevention of transfusion-associated graft-versus-host disease adequate for newborns?
Transfusion medicine (Oxford, England) 1997;7(2):172-3.
1997: Kyle R A; Anderson K C
A tribute to Jan Gosta Waldenström.
Blood 1997;89(12):4245-7.
1997: Soiffer R J; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1997;3(1):11-7.
1997: Soiffer R J; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman R L; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Blood 1997;89(8):3039-47.
1997: Hardy L; Goodman M; Vasquez A; Chauhan D; Anderson K C; Voellmy R; Spector N L
Activation signals regulate heat shock transcription factor 1 in human B lymphocytes.
Journal of cellular physiology 1997;170(3):235-40.
1997: Teoh G; Anderson K C
Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma.
Hematology/oncology clinics of North America 1997;11(1):27-42.
1997: Webb I J; Anderson K C
Transfusion support in acute leukemias.
Seminars in oncology 1997;24(1):141-6.
1997: Chauhan D; Kharbanda S; Ogata A; Urashima M; Teoh G; Robertson M; Kufe D W; Anderson K C
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.
Blood 1997;89(1):227-34.
1997: Schlossman R L; Anderson K C
Bone marrow transplantation in multiple myeloma.
Cancer investigation 1997;15(1):65-75.
1996: Vidriales M B; Anderson K C
Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies.
Molecular medicine today 1996;2(10):425-31.
1996: Hume H A; Popovsky M A; Benson K; Glassman A B; Hines D; Oberman H A; Pisciotto P T; Anderson K C
Hypotensive reactions: a previously uncharacterized complication of platelet transfusion?
Transfusion 1996;36(10):904-9.
1996: Urashima M; Hoshi Y; Sugimoto Y; Kaihara C; Matsuzaki M; Chauhan D; Ogata A; Teoh G; DeCaprio J A; Anderson K C
A novel pre-B acute lymphoblastic leukemia cell line with chromosomal translocation between p16(INK4A)/p15(INK4B) tumor suppressor and immunoglobulin heavy chain genes: TGFbeta/IL-7 inhibitory signaling mechanism.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(10):1576-83.
1996: Freedman A S; Gribben J G; Neuberg D; Mauch P; Soiffer R J; Anderson K C; Pandite L; Robertson M J; Kroon M; Ritz J; Nadler L M
High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission.
Blood 1996;88(7):2780-6.
1996: Webb I J; Coral F S; Andersen J W; Elias A D; Finberg R W; Nadler L M; Ritz J; Anderson K C
Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering.
Transfusion 1996;36(9):782-8.
1996: Urashima M; Ogata A; Chauhan D; Vidriales M B; Teoh G; Hoshi Y; Schlossman R L; DeCaprio J A; Anderson K C
Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein.
Blood 1996;88(6):2219-27.
1996: Dedera D A; Urashima M; Chauhan D; LeBrun D P; Bronson R T; Anderson K C
Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice.
British journal of haematology 1996;94(1):53-61.
1996: Urashima M; Chauhan D; Hatziyanni M; Ogata A; Hollenbaugh D; Aruffo A; Anderson K C
CD40 ligand triggers interleukin-6 mediated B cell differentiation.
Leukemia research 1996;20(6):507-15.
1996: Ogata A; Anderson K C
Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth.
Leukemia research 1996;20(4):303-7.
1996: Urashima M; Ogata A; Chauhan D; Hatziyanni M; Vidriales M B; Dedera D A; Schlossman R L; Anderson K C
Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.
Blood 1996;87(5):1928-38.
1996: Webb I J; Eickhoff C E; Elias A D; Ayash L J; Wheeler C A; Schwartz G N; Demetri G D; Anderson K C
Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections.
Transfusion 1996;36(2):160-7.
1996: Ohto H; Anderson K C
Posttransfusion graft-versus-host disease in Japanese newborns.
Transfusion 1996;36(2):117-23.
1996: Chauhan D; Uchiyama H; Akbarali Y; Urashima M; Yamamoto K; Libermann T A; Anderson K C
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.
Blood 1996;87(3):1104-12.
1996: Ohto H; Anderson K C
Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients.
Transfusion medicine reviews 1996;10(1):31-43.
1996: Federowicz I; Barrett B B; Andersen J W; Urashima M; Popovsky M A; Anderson K C
Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage.
Transfusion 1996;36(1):21-8.
1996: Seiden M V; Anderson K C
Stem cell purging ex vivo.
The Journal of infusional chemotherapy 1996;6(1):17-22.
1995: Chauhan D; Kharbanda S M; Ogata A; Urashima M; Frank D; Malik N; Kufe D W; Anderson K C
Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells.
The Journal of experimental medicine 1995;182(6):1801-6.
1995: Anderson K C
Transfusion medicine.
Current opinion in hematology 1995;2(6):468-71.
1995: Vaickus L; Breitmeyer J B; Schlossman R L; Anderson K C
Platelet transfusion and alternatives to transfusion in patients with malignancy.
Stem cells (Dayton, Ohio) 1995;13(6):588-96.
1995: Anderson K C
Current trends: evolving concepts in transfusion medicine. Leukodepleted cellular blood components for prevention of transfusion-associated graft-versus-host disease.
Transfusion science 1995;16(3):265-8.
1995: Chauhan D; Uchiyama H; Urashima M; Yamamoto K; Anderson K C
Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells.
Stem cells (Dayton, Ohio) 1995;13 Suppl 2():35-9.
1995: Popovsky M A; Benson K; Glassman A B; Hume H; Oberman H A; Pisciotto P T; Anderson K C
Transfusion practices in human immunodeficiency virus-infected patients.
Transfusion 1995;35(7):612-6.
1995: Anderson K C
Who benefits from high-dose therapy for multiple myeloma?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(6):1291-6.
1995: Chauhan D; Kharbanda S M; Uchiyama H; Urashima M; Anderson K C
Activation of pp90rsk and early growth response-1 gene expression by pokeweed mitogen in human B cells.
Leukemia research 1995;19(5):337-44.
1995: Urashima M; Chauhan D; Uchiyama H; Freeman G J; Anderson K C
CD40 ligand triggered interleukin-6 secretion in multiple myeloma.
Blood 1995;85(7):1903-12.
1995: Dzieczkowski J S; McGonigal M; Cook J; Sugrue M; Andersen J; Anderson K C
A comparison of peripheral blood stem cell apheresis using the Fenwal CS3000 Plus and COBE Spectra.
Transfusion science 1995;16(1):71-7.
1995: Goodnough L T; Anderson K C
Recombinant growth factors.
Transfusion science 1995;16(1):45-62.
1995: Dzieczkowski J S; Barrett B B; Nester D; Campbell M; Cook J; Sugrue M; Andersen J W; Anderson K C
Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components.
Transfusion 1995;35(1):20-5.
1995: Biggs D D; Kraj P; Goldman J; Jefferies L; Carchidi C; Anderson K; Silberstein L E
Immunoglobulin gene sequence analysis to further assess B-cell origin of multiple myeloma.
Clinical and diagnostic laboratory immunology 1995;2(1):44-52.
1995: Anderson K C
Autologous peripheral blood progenitor cell transplantation.
Journal of clinical apheresis 1995;10(3):131-8.
1994: Anderson K C
Transfusion medicine.
Current opinion in hematology 1994;1(6):435-7.
1994: Goldmacher V S; Bourret L A; Levine B A; Rasmussen R A; Pourshadi M; Lambert J M; Anderson K C
Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.
Blood 1994;84(9):3017-25.
1994: Chauhan D; Kharbanda S; Uchiyama H; Urashima M; Fragoso R; Sen J; Kufe D W; Anderson K C
Identification of upstream signals regulating interleukin-6 gene expression during in vitro treatment of human B cells with pokeweed mitogen.
Blood 1994;84(7):2243-52.
1994: Shivdasani R A; Anderson K C
HLA homozygosity and shared HLA haplotypes in the development of transfusion-associated graft-versus-host disease.
Leukemia & lymphoma 1994;15(3-4):227-34.
1994: Kim I; Uchiyama H; Chauhan D; Anderson K C
Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines.
British journal of haematology 1994;87(3):483-93.
1994: Stehling L; Luban N L; Anderson K C; Sayers M H; Long A; Attar S; Leitman S F; Gould S A; Kruskall M S; Goodnough L T
Guidelines for blood utilization review.
Transfusion 1994;34(5):438-48.
1994: O'Day S J; Rabinowe S N; Neuberg D; Freedman A S; Soiffer R J; Spector N A; Robertson M J; Anderson K; Whelan M; Pesek K
A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission.
Blood 1994;83(9):2707-14.
1994: Chauhan D; Kharbanda S M; Uchiyama H; Sukhatme V P; Kufe D W; Anderson K C
Involvement of serum response element in okadaic acid-induced EGR-1 transcription in human T-cells.
Cancer research 1994;54(8):2234-9.
1994: Uchiyama H; Anderson K C
Cellular adhesion molecules.
Transfusion medicine reviews 1994;8(2):84-95.
1994: Anderson K C
Current trends: evolving concepts in transfusion medicine: potential alternatives to platelet transfusion.
Transfusion science 1994;15(1):63-5.
1994: Seiden M V; Anderson K C
Multiple myeloma.
Current opinion in oncology 1994;6(1):41-9.
1994: Anderson K C
Preparation and clinical utility of leukocyte-reduced platelets.
Current studies in hematology and blood transfusion 1994;(60):18-28.
1993: Uchiyama H; Barut B A; Mohrbacher A F; Chauhan D; Anderson K C
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.
Blood 1993;82(12):3712-20.
1993: Barut B; Chauhan D; Uchiyama H; Anderson K C
Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro.
The Journal of clinical investigation 1993;92(5):2346-52.
1993: Goodnough L T; Anderson K C; Kurtz S; Lane T A; Pisciotto P T; Sayers M H; Silberstein L E
Indications and guidelines for the use of hematopoietic growth factors.
Transfusion 1993;33(11):944-59.
1993: Anderson K C; Andersen J; Soiffer R; Freedman A S; Rabinowe S N; Robertson M J; Spector N; Blake K; Murray C; Freeman A
Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma.
Blood 1993;82(8):2568-76.
1993: Soiffer R J; Roy D C; Gonin R; Murray C; Anderson K C; Freedman A S; Rabinowe S N; Robertson M J; Spector N; Pesek K
Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse.
Bone marrow transplantation 1993;12(3):243-51.
1993: Shivdasani R A; Anderson K C
Transfusion-associated graft-versus-host disease: scratching the surface.
Transfusion 1993;33(9):696-7.
1993: Tepler I; Cannistra S A; Frei E; Gonin R; Anderson K C; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1583-91.
1993: Pisciotto P T; Anderson K C; Goodnough L T; Kurtz S R; Lane T A; Sayers M H; Silberstein L E
Current trends: evolving concepts in transfusion medicine. The need for standardization of cryoprecipitate-derived fibrin adhesive.
Transfusion science 1993;14(3):291-4.
1993: Freedman A S; Takvorian T; Neuberg D; Mauch P; Rabinowe S N; Anderson K C; Soiffer R J; Spector N; Grossbard M; Robertson M J
Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):931-6.
1993: Stroncek D F; Holland P V; Bartch G; Bixby T; Simmons R G; Antin J H; Anderson K C; Ash R C; Bolwell B J; Hansen J A
Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program.
Blood 1993;81(7):1940-6.
1993: Chauhan D; Kharbanda S M; Rubin E; Barut B A; Mohrbacher A; Kufe D W; Anderson K C
Regulation of c-jun gene expression in human T lymphocytes.
Blood 1993;81(6):1540-8.
1993: Barrett B B; Andersen J W; Anderson K C
Strategies for the avoidance of bacterial contamination of blood components.
Transfusion 1993;33(3):228-33.
1993: Shivdasani R A; Haluska F G; Dock N L; Dover J S; Kineke E J; Anderson K C
Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors.
The New England journal of medicine 1993;328(11):766-70.
1992: Anderson K C; Morimoto C; Paul S R; Chauhan D; Williams D; Cochran M; Barut B A
Interleukin-11 promotes accessory cell-dependent B-cell differentiation in humans.
Blood 1992;80(11):2797-804.
1992: Uchiyama H; Barut B A; Chauhan D; Cannistra S A; Anderson K C
Characterization of adhesion molecules on human myeloma cell lines.
Blood 1992;80(9):2306-14.
1992: Barut B A; Zon L I; Cochran M K; Paul S R; Chauhan D; Mohrbacher A; Fingeroth J; Anderson K C
Role of interleukin 6 in the growth of myeloma-derived cell lines.
Leukemia research 1992;16(10):951-9.
1992: Soiffer R J; Murray C; Mauch P; Anderson K C; Freedman A S; Rabinowe S N; Takvorian T; Robertson M J; Spector N; Gonin R
Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(7):1191-200.
1992: Lane T A; Anderson K C; Goodnough L T; Kurtz S; Moroff G; Pisciotto P T; Sayers M; Silberstein L E
Leukocyte reduction in blood component therapy.
Annals of internal medicine 1992;117(2):151-62.
1992: Elias A D; Ayash L; Anderson K C; Hunt M; Wheeler C; Schwartz G; Tepler I; Mazanet R; Lynch C; Pap S
Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.
Blood 1992;79(11):3036-44.
1992: Robertson M J; Soiffer R J; Freedman A S; Rabinowe S L; Anderson K C; Ervin T J; Murray C; Dear K; Griffin J D; Nadler L M
Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia.
Blood 1992;79(9):2229-36.
1992: Anderson K C
The role of the blood bank in hematopoietic stem cell transplantation.
Transfusion 1992;32(3):272-85.
1992: Sayers M H; Anderson K C; Goodnough L T; Kurtz S R; Lane T A; Pisciotto P; Silberstein L E
Reducing the risk for transfusion-transmitted cytomegalovirus infection.
Annals of internal medicine 1992;116(1):55-62.
1992: Paul S R; Barut B A; Bennett F; Cochran M A; Anderson K C
Lack of a role of interleukin 11 in the growth of multiple myeloma.
Leukemia research 1992;16(3):247-52.
1991: Soiffer R J; Dear K; Rabinowe S N; Anderson K C; Freedman A S; Murray C; Tarbell N J; Mauch P; Nadler L M; Ritz J
Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation.
Transplantation 1991;52(6):1014-9.
1991: Elias A D; Mazanet R; Wheeler C; Anderson K; Ayash L; Schwartz G; Tepler I; Pap S; Pelaez J; Hunt M
GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols.
Breast cancer research and treatment 1991;20 Suppl():S25-9.
1991: Matsuyama T; Yamada A; Rothstein D M; Anderson K C; Schlossman S F; Morimoto C
CD45 isoforms associated with distinct functions of CD4 cells derived from unusual healthy donors lacking CD45RA- T lymphocytes.
Cellular immunology 1991;137(2):406-19.
1991: Robertson M J; Socinski M A; Soiffer R J; Finberg R W; Wilson C; Anderson K C; Bosserman L; Sang D N; Salkin I F; Ritz J
Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia.
Bone marrow transplantation 1991;8(2):143-5.
1991: Freedman A S; Ritz J; Neuberg D; Anderson K C; Rabinowe S N; Mauch P; Takvorian T; Soiffer R; Blake K; Yeap B
Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma.
Blood 1991;77(11):2524-9.
1991: Anderson K C; Goodnough L T; Sayers M; Pisciotto P T; Kurtz S R; Lane T A; Anderson C S; Silberstein L E
Variation in blood component irradiation practice: implications for prevention of transfusion-associated graft-versus-host disease.
Blood 1991;77(10):2096-102.
1991: Rabinowe S N; Soiffer R J; Tarbell N J; Neuberg D; Freedman A S; Seifter J; Blake K W; Gribben J G; Anderson K C; Takvorian T
Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies.
Blood 1991;77(8):1837-44.
1991: Anderson K C; Barut B A; Ritz J; Freedman A S; Takvorian T; Rabinowe S N; Soiffer R; Heflin L; Coral F; Dear K
Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma.
Blood 1991;77(4):712-20.
1991: Soiffer R J; Mauch P; Tarbell N J; Anderson K C; Freedman A S; Rabinowe S N; Takvorian T; Murrey C I; Coral F; Bosserman L
Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow.
Bone marrow transplantation 1991;7(1):23-33.
1990: Jochelson M; Tarbell N J; Freedman A S; Rabinowe S N; Takvorian T; Soiffer R; Anderson K; Ritz J; Nadler L M
Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma.
Bone marrow transplantation 1990;6(5):329-31.
1990: Barut B A; Cochran M K; O'Hara C; Anderson K C
Response patterns of hairy cell leukemia to B-cell mitogens and growth factors.
Blood 1990;76(10):2091-7.
1990: Goodnough L T; Johnston M F; Ramsey G; Sayers M H; Eisenstadt R S; Anderson K C; Rutman R C; Silberstein L E
Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Transfusion Practices Committee of the American Association of Blood Banks.
The Annals of thoracic surgery 1990;50(4):675-83.
1990: Anderson K C; Weinstein H J
Transfusion-associated graft-versus-host disease.
The New England journal of medicine 1990;323(5):315-21.
1990: Licht J D; Bosserman L D; Andersen J W; Yeap B Y; Klatt M M; Martel J K; Anderson K C; Rosenthal D S; Pinkus G; Skarin A T
Treatment of low-grade and intermediate-grade lymphoma with intensive combination chemotherapy results in long-term, disease-free survival.
Cancer 1990;66(4):632-9.
1990: Anderson K C; Soiffer R; DeLage R; Takvorian T; Freedman A S; Rabinowe S L; Nadler L M; Dear K; Heflin L; Mauch P
T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications.
Blood 1990;76(1):235-44.
1990: Anderson K C; Braine H G
Specialized cell component therapy.
Seminars in oncology nursing 1990;6(2):140-9.
1990: Freedman A S; Takvorian T; Anderson K C; Mauch P; Rabinowe S N; Blake K; Yeap B; Soiffer R; Coral F; Heflin L
Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(5):784-91.
1990: Delage R; Ritz J; Anderson K C
The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia.
Hematology/oncology clinics of North America 1990;4(2):369-88.
1990: Roy D C; Tantravahi R; Murray C; Dear K; Gorgone B; Anderson K C; Freedman A S; Nadler L M; Ritz J
Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium.
Blood 1990;75(1):296-304.
1989: Nakamura M; Merchav S; Carter A; Ernst T J; Demetri G D; Furukawa Y; Anderson K; Freedman A S; Griffin J D
Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(11):3543-7.
1989: Pedrazzini A; Freedman A S; Andersen J; Heflin L; Anderson K; Takvorian T; Canellos G P; Whitman J; Coral F; Ritz J
Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function.
Blood 1989;74(6):2203-11.
1989: Young L; Alfieri C; Hennessy K; Evans H; O'Hara C; Anderson K C; Ritz J; Shapiro R S; Rickinson A; Kieff E
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.
The New England journal of medicine 1989;321(16):1080-5.
1989: Anderson K C; Jones R M; Morimoto C; Leavitt P; Barut B A
Response patterns of purified myeloma cells to hematopoietic growth factors.
Blood 1989;73(7):1915-24.
1989: Bosserman L D; Murray C; Takvorian T; Anderson K C; Freedman A S; Fitzsimmons J; Coral F; Nadler L M; Schlossman S F; Ritz J
Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients.
Bone marrow transplantation 1989;4(3):239-45.
1989: Greipp P R; Coleman M; Anderson K; McIntyre O R
Phase II trial of amsacrine in patients with multiple myeloma.
Medical and pediatric oncology 1989;17(1):76-8.
1989: Anderson K C; Barut B A; Ritz J; Freedman A S; Nadler L M
Autologous bone marrow transplantation therapy for multiple myeloma.
European journal of haematology. Supplementum 1989;51():157-63.
1989: Anderson K C; Cochran M; Barut B A
Phenotypic and functional characterization of normal and malignant terminal B (plasma) cells.
European journal of haematology. Supplementum 1989;51():19-26.
1988: Freedman A S; Takvorian T; Nadler L M; Anderson K C; Sallan S E; Ritz J
Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement.
Cancer treatment and research 1988;38():265-83.
1987: Takvorian T; Canellos G P; Ritz J; Freedman A S; Anderson K C; Mauch P; Tarbell N; Coral F; Daley H; Yeap B
Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis.
The New England journal of medicine 1987;316(24):1499-505.
1987: Anderson K C; Ritz J; Takvorian T; Coral F; Daley H; Gorgone B C; Freedman A S; Canellos G P; Schlossman S F; Nadler L M
Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow.
Blood 1987;69(2):597-604.
1987: Anderson K C; Nadler L M; Takvorian T; Freedman A S; Canellos G P; Schlossman S F; Ritz J
Monoclonal antibodies: their use in bone marrow transplantation.
Progress in hematology 1987;15():137-81.
1986: Bell W R; Anderson K C; Noe D A; Silver B A
Reduction in the plasma clearance rate of warfarin induced by cimetidine.
Archives of internal medicine 1986;146(12):2325-8.
1986: Anderson K C; Gorgone B C; Marlink R G; Ferriani R; Essex M E; Benz P M; Groopman J E
Transfusion-acquired human immunodeficiency virus infection among immunocompromised persons.
Annals of internal medicine 1986;105(4):519-27.
1986: Anderson K C; Lew M A; Gorgone B C; Martel J; Leamy C B; Sullivan B
Transfusion-related sepsis after prolonged platelet storage.
The American journal of medicine 1986;81(3):405-11.
1986: Cooper M R; McIntyre O R; Propert K J; Kochwa S; Anderson K; Coleman M; Kyle R A; Prager D; Rafla S; Zimmer B
Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(9):1331-9.
1986: Anderson K C; Jamison D S; Peters W P; Li F P
Familial Burkitt's lymphoma. Association with altered lymphocyte subsets in family members.
The American journal of medicine 1986;81(1):158-62.
1986: Anderson K C; Roach J A; Daley J F; Schlossman S F; Nadler L M
Dual fluorochrome analysis of human B lymphocytes: phenotypic examination of resting, anti-immunoglobulin stimulated, and in vivo activated B cells.
Journal of immunology (Baltimore, Md. : 1950) 1986;136(10):3612-8.
1986: Boyd A W; Freedman A S; Horowitz J C; Anderson K C; Fisher D C; Rosen K J; Schlossman S F; Nadler L M
Studies of the in vitro activation and differentiation of human B lymphocytes. II. Optimization of activation by anti-immunoglobulin antibody bound to beads: analysis of the role of autocrine effects on B-cell proliferation and of T-cell help in B-cell differentiation.
Cellular immunology 1986;99(1):228-40.
1986: Hercend T; Takvorian T; Nowill A; Tantravahi R; Moingeon P; Anderson K C; Murray C; Bohuon C; Ythier A; Ritz J
Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation.
Blood 1986;67(3):722-8.
1986: Anderson K C; Simpson W G; Ballou R J; Harty J I; Tseng M T
In vitro chemosensitivity of J-82 human bladder cancer cells.
Urological research 1986;14(3):141-4.
1986: Anderson K C; Nadler L M
Bone marrow transplantation in the therapy of non-Hodgkin's lymphomas.
Important advances in oncology 1986;():287-310.
1985: Anderson K C; Kaplan W D; Leonard R C; Skarin A T; Canellos G P
Role of 99mTc methylene diphosphonate bone imaging in the management of lymphoma.
Cancer treatment reports 1985;69(12):1347-51.
1985: Freedman A S; Boyd A W; Anderson K C; Fisher D C; Schlossman S F; Nadler L M
B5, a new B cell-restricted activation antigen.
Journal of immunology (Baltimore, Md. : 1950) 1985;134(4):2228-35.
1985: Vinciguerra V; Anderson K; McIntyre O R
Diaziquone for resistant multiple myeloma. Cancer and Leukemia Group B.
Cancer treatment reports 1985;69(3):331-2.
1985: Freedman A S; Boyd A W; Anderson K C; Fisher D C; Pinkus G S; Schlossman S F; Nadler L M
Immunologic heterogeneity of diffuse large cell lymphoma.
Blood 1985;65(3):630-7.
1985: Anderson K C; Boyd A W; Fisher D C; Leslie D; Schlossman S F; Nadler L M
Hairy cell leukemia: a tumor of pre-plasma cells.
Blood 1985;65(3):620-9.
1985: Boyd A W; Anderson K C; Freedman A S; Fisher D C; Slaughenhoupt B; Schlossman S F; Nadler L M
Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody.
Journal of immunology (Baltimore, Md. : 1950) 1985;134(3):1516-23.
1985: Anderson K C; Boyd A W; Fisher D C; Slaughenhoupt B; Groopman J E; O'Hara C J; Daley J F; Schlossman S F; Nadler L M
Isolation and functional analysis of human B cell populations. I. Characterization of the B1+B2+ and B1+B2- subsets.
Journal of immunology (Baltimore, Md. : 1950) 1985;134(2):820-7.
1984: Anderson K C; Skarin A T; Rosenthal D S; MacIntyre J M; Pinkus G S; Case D C; Leonard R C; Canellos G P
Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
Cancer treatment reports 1984;68(11):1343-50.
1984: Simpson W G; Tseng M T; Anderson K C; Harty J I
Verapamil enhancement of chemotherapeutic efficacy in human bladder cancer cells.
The Journal of urology 1984;132(3):574-6.
1984: Nadler L M; Korsmeyer S J; Anderson K C; Boyd A W; Slaughenhoupt B; Park E; Jensen J; Coral F; Mayer R J; Sallan S E
B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation.
The Journal of clinical investigation 1984;74(2):332-40.
1984: Anderson K C; Bates M P; Slaughenhoupt B L; Pinkus G S; Schlossman S F; Nadler L M
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation.
Blood 1984;63(6):1424-33.
1984: Anderson K C; Bates M P; Slaughenhoupt B; Schlossman S F; Nadler L M
A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells.
Journal of immunology (Baltimore, Md. : 1950) 1984;132(6):3172-9.
1983: Anderson K C; Leonard R C; Canellos G P; Skarin A T; Kaplan W D
High-dose gallium imaging in lymphoma.
The American journal of medicine 1983;75(2):327-31.
1983: Nadler L A; Anderson K C; Schlossman S F
Human T and B cell derived malignancies.
[Rinsho ketsueki] The Japanese journal of clinical hematology 1983;24(8):987-95.
1983: Nadler L M; Anderson K C; Marti G; Bates M; Park E; Daley J F; Schlossman S F
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1983;131(1):244-50.
1983: Anderson K C; Griffin J D; Bates M P; Slaughenhoupt B L; Schlossman S F; Nadler L M
Isolation and characterization of human B lymphocyte enriched populations. I. Purification of B cells by immune rosette depletion.
Journal of immunological methods 1983;61(3):283-92.
1983: Anderson K C; Garnick M B; Meshad M W; Cohen G I; Pegg W J; Frei E; Israel M; Modest E; Canellos G P
Phase I trial of mitoxantrone by 24-hour continuous infusion.
Cancer treatment reports 1983;67(5):435-8.
1983: Anderson K C; Humphrey R L; Sensenbrenner L L
Predictive values of the in vivo diffusion chamber for cyclophosphamide treatment of L1210 murine leukemia.
Cancer research 1983;43(5):2030-3.
1983: Anderson K C; Park E K; Bates M P; Leonard R C; Hardy R; Schlossman S F; Nadler L M
Antigens on human plasma cells identified by monoclonal antibodies.
Journal of immunology (Baltimore, Md. : 1950) 1983;130(3):1132-8.
1982: Anderson K C; Cohen G I; Garnick M B
Phase II trial of mitoxantrone.
Cancer treatment reports 1982;66(11):1929-31.
1982: Nadler L M; Ritz J; Bates M P; Park E K; Anderson K C; Sallan S E; Schlossman S F
Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia.
The Journal of clinical investigation 1982;70(2):433-42.
1982: Klein H G; Kessler C; Anderson K C; Loomis K F
Multiple arterial and venous thromboemboli in a man with chronic myelogenous leukemia and occult metastatic breast carcinoma: the significance of thrombocythemia.
Southern medical journal 1982;75(6):745-7.
1982: Bo-Linn G W; Anderson D J; Anderson K C; McGoon M D
Percutaneous central venous catheterization performed by medical house officers: a prospective study.
Catheterization and cardiovascular diagnosis 1982;8(1):23-9.
1981: Anderson K C; Kuhajda F P; Bell W R
Diagnosis and treatment of anticoagulant-related adrenal hemorrhage.
American journal of hematology 1981;11(4):379-85.
1981: Greenberg M S; Anderson K C; Marchetto D J; Li F P
Acute myelocytic leukemia in two brothers with polyposis coli and carcinoma of the colon.
Annals of internal medicine 1981;95(6):702-3.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Kenneth Anderson

Research Profile (preview)

Disorders

Chemicals & Drugs

Anatomy

Physiology

Living Beings

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Kenneth Anderson (preview)

All Publications